ORIGINAL RESEARCH

Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9 Million US Veterans

Melissa Soohoo, MPH; Leila Hashemi , MS, MD; Jui-Ting Hsiung, MPH; Hamid Moradi, MD; Matthew J. Budoff , MD; Csaba P. Kovesdy, MD; Kamyar Kalantar-Zadeh, MD, MPH, PhD; Elani Streja , MPH, PhD

BACKGROUND: High triglycerides are associated with atherosclerotic cardiovascular disease (ASCVD) risks. Among patients with advanced chronic kidney disease (CKD), the association of elevated triglycerides with mortality is diminished and, thus, we investigated the relationship of triglycerides with ASCVD and non-ASCVD hospitalizations across CKD stages.

METHODS AND RESULTS: The cohort comprised 2 963 176 veterans who received care in 2004 to 2006 (baseline) and were followed up to 2014. Using Cox models, we evaluated baseline and time-varying triglycerides with time to ASCVD or non-ASCVD hospitalizations, stratified by baseline CKD stage, and adjusted for demographics and baseline or time-updated clinical characteristics. The cohort mean±SD age was 63±14 years, with a baseline median (interquartile range) triglycerides level of 127 (87–189) mg/dL, and a quarter had prevalent CKD. There was a linear association between baseline triglycerides and ASCVD risk; however, the risk with high triglycerides ≥240 mg/dL attenuated with worsening CKD stages (reference: triglycerides 120 to <160 mg/dL). Baseline triglycerides were associated with a U-shaped relationship for non-ASCVD events in patients with CKD 3A to 3B. Patients with late-stage CKD had lower to null relationships between baseline triglycerides and non-ASCVD events. Time-varying triglycerides associations with ASCVD were similar to baseline analyses. Yet, the time-varying triglycerides relationship with non-ASCVD events was inverse and linear, where elevated triglycerides were associated with lower risks.

CONCLUSIONS: Associations of higher triglycerides with ASCVD and non-ASCVD events declined across advancing CKD stages, where a lower to null risk was observed in patients with advanced CKD. Studies are needed to examine the impact of advanced CKD on triglycerides metabolism and its association with outcomes in this high-risk population.

Key Words: atherosclerosis Statistics Itriglycerides

yslipidemia, including elevated serum triglycerides, is a risk factor for atherogenesis and development of cardiovascular disease (CVD) and is thus a primary target for CVD prevention in the general population.¹⁻³ Studies have suggested that hypertriglyceridemia is a predictor for chronic kidney

JAHA is available at: www.ahajournals.org/journal/jaha

Correspondence to: Elani Streja, MPH, PhD, VA Long Beach Healthcare System, 5901 E 7th St, Long Beach, CA 90822. E-mail: elani.streja@va.gov Data were presented as an oral presentation at the American Heart Association Scientific Sessions, November 16–18, 2019, in Philadelphia, PA, and as a poster presentation at the virtual American Society for Nephrology Kidney Week meeting, October 19–25, 2020.

Supplementary Material for this article is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.022988

For Sources of Funding and Disclosures, see page 9.

^{© 2021} The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

CLINICAL PERSPECTIVE

What Is New?

- Elevated triglycerides are associated with higher risk of atherosclerotic and nonatherosclerotic cardiovascular disease events yet not in patients with advanced chronic kidney disease.
- These relationships persisted in evaluating longand short-term measurements of triglycerides.

What Are the Clinical Implications?

 It is imperative to understand the immediate and long-term impact of triglycerides on these cardiovascular events in patients with chronic kidney disease as to best manage cardiovascular health.

Nonstandard Abbreviations and Acronyms

SHARP	Study of Heart and Renal Protection
UACR	urine albumin/creatinine ratio
VA	Veterans Affairs

disease (CKD), including its development and progression into advanced CKD stages.^{4,5} Because of lipid aberrations and accelerated atherosclerosis during CKD progression, these patients have a higher burden and risk of atherosclerotic cardiovascular disease (ASCVD), non-ASCVD, and mortality compared with the general population.⁶⁻⁹ We previously demonstrated that the association between high serum triglycerides with CVD mortality incrementally declined across worsening CKD stages, where it reached a null association in patients with CKD stage 5 and end-stage renal disease (ESRD).¹⁰ Possible explanations include competing events of other CVD causes, such as nonfatal CVD hospitalizations.^{5,10,11} Clinical trials have focused on ASCVD events in patients with CKD, including primarily targeting low-density lipoprotein cholesterol (LDL-C) levels in early CKD stages (3A-3B), while the trials have been null in the patients with advanced CKD.¹² Thus, understanding the relationship between other components of dyslipidemia, such as triglycerides, with CVD outcomes is critical for devising risk mitigation strategies, especially in patients with advanced CKD.

Prior studies examining serum lipids with CVD events in patients with CKD have found mixed results, and have primarily investigated patients with early-stage CKD.^{13–16} Understanding both the long- and short-term relationships of triglycerides on CVD events may better elucidate their complex relationships as CKD progresses to advanced stages. Moreover, studies have often focused on the relationship of triglycerides with composite CVD or ASCVD only events given that they are targeted by pharmacologic therapies, but the relationship of triglycerides with vascular yet non-ASCVD events remains less known. Therefore, using a large national cohort, we hypothesized that the relationships between baseline and time-varying serum triglycerides with ASCVD and non-ASCVD are also impacted by worsening CKD stages.

METHODS

Data Availability

Restrictions apply to the availability of data generated or analyzed during this study. The US Department of Veterans Affairs (VA) places legal restrictions on access to veteran's health care data, which includes both identifying data and sensitive patient information. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

Study Population and Longitudinal Construction

The LIPROVET (Lipid Profiles and Management in Veterans With CKD) study is composed of US VA patients, with a lipid measurement between October 1, 2004, and September 30, 2006 (baseline period).¹⁰ Follow-up was divided into consecutive calendar quarters (91-day intervals), starting from the quarter of the patient's first triglycerides and estimated glomerular filtration rate (eGFR) measurement in the baseline period. We excluded 114 031 patients for missing a triglycerides measurement during baseline, 880 985 patients for missing an eGFR measurement, 98 patients with invalid censoring information, and 547 patients for missing data on hospitalization during follow-up. The final cohort included 2 963 176 patients (Figure S1).

Clinical Measurements

The ascertainment of characteristics has been described elsewhere.¹⁰ Data were sourced from combined VA, Centers for Medicare and Medicaid Services, and the US Renal Data System databases. The VA databases informed ever smoker and alcoholism statuses, which were defined as any indication of the behavior until censorship.¹⁷ VA/Centers for Medicare and Medicaid Services pharmacy records identified lipidmodulating therapy prescriptions based on drug class codes and names. Receipt of medication was defined as any dispensation recorded within each calendar quarter. Comorbidities were derived from VA/Centers for Medicare and Medicaid Services databases using *International Classification of Diseases, Ninth* *Revision (ICD-9)* Diagnostic and Current Procedural Terminology, and were updated for each quarter.^{18,19}

Laboratory measurements were extracted from the VA database. The Martin-Hopkins equation was used to calculate LDL-C if missing for any quarter.²⁰ eGFR was calculated from serum creatinine using the CKD Epidemiology Collaboration formula.²¹ CKD stage according to non-dialysis-dependent eGFR cutoffs was categorized as non-CKD, 3A, 3B, 4, and 5. The US Renal Data System identified patients with ESRD on renal replacement therapy, and they were grouped with CKD stage 5 irrespective of eGFR. All laboratory measurements were averaged per patient per calendar quarter to minimize measurement variability.

Exposure and Outcome Assessment

On the basis of clinically relevant cutoffs and prior studies, baseline and time-varying triglycerides were categorized as follows: <80, 80 to <120, 120 to <160, 160 to <200, 200 to <240, and \geq 240 mg/dL.^{10,22,23}

The outcomes were time to (1) ASCVD and (2) non-ASCVD hospitalization. VA/Centers for Medicare and Medicaid Services records with the specific diagnostic code in the first or second position were considered as an event (Table 1). Definitions of ASCVD and non-ASCVD hospitalizations were based on clinician judgment and prior studies.^{13,14,24} Information on other censoring events was obtained from the aforementioned sources and the National Death Index. Patient follow-up started at the calendar quarter of entry, and ended at death, lost to follow-up, first ASCVD or non-ASCVD hospitalization if the outcome of interest, or December 31, 2014, whichever occurred first.

Statistical Analysis

Baseline characteristics are presented as mean±SD, median (interquartile range), or percentage, as appropriate.

We used Cox models to evaluate the association of baseline or time-varying triglycerides with time to ASCVD or non-ASCVD hospitalization, stratified by baseline CKD stage. In all analyses, the reference group was triglycerides 120 to <160 mg/dL.

Five adjustment models were examined: (1) unadjusted; (2) age adjusted; (3) case-mix adjusted, which included age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins, and prescription of nonstatins; (4) case-mix+laboratory adjusted, which additionally included body mass index and albumin to the case-mix model; and (5) casemix+laboratory+lipid adjusted, which additionally included LDL-C and high-density lipoprotein cholesterol to the case-mix+laboratory model. For baseline models, data from the baseline quarter were used in analyses. In time-varying models, time-updated comorbidities, medications, and laboratory measurements were used, as well as time-varying CKD stage in case-mix adjusted and higher models. We predefined the case-mix+laboratory adjustment as the model of interest.

We performed competing risk regression to account for mortality, where ASCVD hospitalization was competed against all-cause mortality and non-ASCVD hospitalization, and vice versa when non-ASCVD hospitalization was the outcome.²⁵ We evaluated the triglycerides-hospitalization relationships in subgroup analyses of baseline characteristics to investigate effect modification. In sensitivity analyses, we evaluated the relationship of baseline triglycerides and urinary tract infection hospitalization to investigate this negative control outcome in addressing uncontrolled confounding. Moreover, we evaluated

Hospitalization	Event description	ICD-9 codes
ASCVD	Myocardial infarction	410, 412
	Unstable angina	411, 413
	Ischemic heart disease-other (coronary artery disease)	414
	Nonhemorrhagic stroke (ischemic TIA)	433–438
	Atherosclerosis (includes PVD and aneurysm)	440–445
Non-ASCVD	Heart failure (includes cardiomyopathy/arrhythmia)	425–429
	Hypertension	401–405
	Hemorrhagic stroke	430–432
	Fatal pulmonary embolism	415
	Phlebitis	451

Table 1. ICD-9 Codes and Causes of ASCVD and Non-ASCVD Hospitalizations

ASCVD indicates atherosclerotic cardiovascular disease; ICD-9, International Classification of Diseases, Ninth Revision; PVD, peripheral vascular disease; and TIA, transient ischemic attack.

194 801 patients with available data on urine albumin/ creatinine ratio (UACR) in the year before the calendar quarter of entry. A comparison of patients with and without UACR data is presented in Table S1. We repeated baseline analyses with adjustment for logtransformed UACR in the case-mix+laboratory model in this select population.

Data were missing in <2% for demographics, and 6% and 22%, respectively, for smoking status and alcoholism at baseline, and were imputed with a missing category. Baseline medications were missing in 5%, and both baseline and time-varying medications were imputed with a missing category. Albumin and body mass index were missing in 25% and 9%, respectively, at baseline, and were imputed by means. A last measurement carried forward imputation was used for all missing time-varying laboratory data, including triglycerides or eGFR.

Analyses were performed using SAS Enterprise Guide (7.1) (Cary, NC) and Stata (15) (College Station, TX). Because of the nonintrusive nature of the research, patient anonymity, and large sample size, the required written consent was waived; and this study was approved by the institutional review board of the Tibor Rubin VA Medical Center of Long Beach, CA.

RESULTS

In our cohort, the mean age (SD) was 63±14 years, and the cohort included 6% women and 14% Black race. The cohort had a median (interquartile range) averaged triglycerides level of 127 (87–189) mg/dL and averaged high-density lipoprotein cholesterol, LDL-C, and total cholesterol levels of 42 (35–51), 104 (83–129), and 178 (153–206) mg/dL, respectively. A quarter of patients had CKD (stage 3A and higher) at baseline, including 0.8% with CKD stage 5 or ESRD. Those with higher triglycerides tended to be younger and White race, have a lower prevalence of chronic obstructive pulmonary disease and anemia, and have a higher prevalence of diabetes, depression, and anxiety (Table 2).

Association of Baseline Triglycerides With Time to Hospitalizations

We observed 756 917 and 952 359 ASCVD and non-ASCVD hospitalizations, respectively, yielding crude incidence rates (95% Cls) of 36.7 (36.6–36.8) ASCVD and 47.3 (47.2–47.4) non-ASCVD events per 1000 person-years. Both rates increased with advancing CKD stage (Table S2). Only 11% and 16% of patients experienced >2 ASCVD or non-ASCVD hospitalizations, respectively, during follow-up. Among patients with any ASCVD hospitalization, 21% experienced a myocardial infarction as their first event, whereas most (35%) experienced other ischemic heart disease as their first ASCVD event. Conversely, 60% of the first non-ASCVD hospitalizations were for heart failure.

In unadjusted models, the relationship of baseline triglycerides and ASCVD hospitalization was generally linear compared with triglycerides 120 to <160 mg/dL (Table S3). After adjustment for case-mix+laboratory covariates, lower triglycerides <120 mg/dL were associated with a lower risk of ASCVD hospitalization across all stages (Figure 1A). Moreover, the magnitude of association for high triglycerides ≥240 mg/dL with ASCVD hospitalization gradually decreased across CKD stages, where those with CKD stage 5/ESRD had an attenuated and null relationship. Adjustment for lipid measurements slightly attenuated results, but they were nonetheless similar.

In unadjusted models, we observed a shallow inverse relationship between baseline triglycerides and non-ASCVD hospitalization across CKD stages (Table S4). Yet, adjustment for case-mix+laboratory covariates demonstrated a U-shaped relationship for patients with CKD stage 3A to 3B, and an inverse relationship for patients with CKD stage 4 and 5/ESRD (Figure 1B). We also observed a gradual cascade in the risk between high triglycerides and non-ASCVD hospitalization across CKD stages. There was a lower to null association between high triglycerides and non-ASCVD hospitalization among patients with CKD stage 4 and 5/ESRD. Similar relationships were observed with additional lipid adjustment.

Sensitivity Analyses of Baseline Triglycerides and Time to Hospitalizations

Our observed relationships were comparable when using a competing risk regression adjusted for casemix+laboratory covariates. We observed a linear association with baseline triglycerides and time to ASCVD hospitalization after considering competing events. Elevated triglycerides were associated with a higher risk for ASCVD events for all CKD stages. In competing risk analyses for non-ASCVD hospitalization, we observed a reverse J-shaped association in casemix+laboratory adjustment.

In sensitivity analyses using a negative control, we found that association of baseline triglycerides with urinary tract infection hospitalization had a lower to null relationship across all CKD stages. A comparison of patients with and without UACR data demonstrated that those with UACR were more likely to be older, have diabetes, have hypertension, and have higher levels of body mass index (Table S1). After adjustment for logtransformed UACR in our main models, we observed

Table 2. Patient Characteristics Stratified by Baseline Serum Triglycerides Group

	Baseline serum triglycerides group, mg/dL									
Total	<80	80-<120	120-<160	160-<200	200-<240	≥240				
2 963 176	594 877 (20)	767 468 (26)	571 781 (19)	368 272 (12)	228 243 (8)	432 535 (15				
76 (62–91)	80 (64–94)	76 (61–90)	75 (61–89)	75 (60–89)	75 (60–90)	77 (61–92)				
1					_1	_l				
77	81	77	75	75	75	77				
15	13	15	16	16	15	14				
6	5	6	7	7	7	7				
2	1	2	2	2	2	2				
0.8	0.7	0.8	0.8	0.8	0.8	0.8				
63±14	63±16	64±14	64±14	63±13	62±13	60±13				
6	8	6	5	5	5	4				
56	54	57	58	58	57	55				
82	75	80	84	85	86	86				
14	22	16	13	11	10	9				
4	3	4	4	4	4	5				
4	4	4	4	4	4	5				
						1 (0-2)				
	. (* _/	. (* _/	. (* _)	. (* _/	. (* _/	. (
7	6	7	7	7	7	6				
						10				
						9				
						8				
						2				
						16				
						3				
						38				
						10				
						9				
						5				
						67 26				
						23				
						16				
						10				
						0.4				
						68				
25	30	20	24	23	22	23				
44.0.1	40.05	40.01	44.04	44.04	44.01	44.01				
						4.1±0.4				
			. ,			24 (20-30)				
						29 (21–41)				
114.4±41.3	105.1±29.8	109.4±33.5	113.6±37.7	117.2±41.8	120.7±45.4	131.7±59.2				
14.5±1.6	14.1±1.6	14.4±1.6	14.6±1.6	14.7±1.6	14.7±1.6	14.8±1.6				
7.2±2.7	6.6±2.6		7.3±2.7	7.4±2.6	7.5±2.6	7.6±2.7				
135±18	133±18	134±18	135±18	136±17	136±17	137±17				
	2 963 176 76 (62–91) 77 15 6 2 0.8 63±14 6 56 82 14 4 4 4 4 1 (0–2) 7 10 10 9 3 18 3 27 10 10 9 3 18 3 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 12 12 7 64 27 12 12 7 64 27 12 12 12 12 7 64 27 12 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 64 27 12 12 7 10 10 9 3 18 3 27 12 12 7 64 27 12 12 7 64 27 12 12 12 12 7 64 27 18 13 7 0.4 64 25 5 114,4±41.3 14,5±1.6 7,2±2.7	2 963 176 594 877 (20) 76 (62–91) 80 (64–94) 77 81 15 13 6 5 2 1 0.8 0.7 63±14 63±16 6 8 56 54 82 75 14 22 4 3 4 4 1 (0–2) 1 (0–2) 7 6 10 10 10 9 9 9 3 4 18 19 3 4 27 20 12 12 12 14 7 8 64 57 27 24 18 15 13 11 7 6 0.4 0.4 25 30 4.1±0.4 4.0±0.5 <td>2 963 176 594 877 (20) 767 468 (26) 76 (62–91) 80 (64–94) 76 (61–90) 77 81 77 15 13 15 6 5 6 2 1 2 0.8 0.7 0.8 63±14 63±16 64±14 6 8 6 56 54 57 82 75 80 14 22 1 4 4 4 1 (0–2) 1 (0–2) 1 (0–2) 7 6 7 10 9 9 3 4 3 18 19 19 3 4 3 27 20 24 12 12 13 18 19 19 3 4 3 27 20 24 12 14 13 <</td> <td>2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 76 (62-91) 80 (64-94) 76 (61-90) 75 (61-89) 77 81 77 75 15 13 15 16 6 5 6 7 2 1 2 2 0.8 0.7 0.8 0.8 63±14 63±16 64±14 64±14 6 8 6 5 56 54 57 58 ***********************************</td> <td>2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 368 272 (12) 76 (62-91) 80 (64-94) 76 (61-90) 75 (61-89) 75 (60-89) 77 81 77 75 75 15 13 15 16 16 6 5 6 7 7 2 1 2 2 2 0.8 0.7 0.8 0.8 0.8 63±14 63±16 64±14 64±14 63±13 6 8 6 5 5 56 54 57 58 58 82 75 80 84 85 14 22 16 13 11 4 3 4 4 4 10-2) 1(0-2) 1(0-2) 1(0-2) 7 6 7 7 7 10 10 10 10 9 9 9 9<td>2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 368 272 (12) 228 243 (8) 76 (62-91) 80 (04-94) 76 (61-90) 75 (61-89) 75 (60-89) 75 (60-90) 77 81 77 75 75 75 75 15 13 15 16 16 15 6 5 6 7 7 7 2 1 2 2 2 2 0.8 0.7 0.8 0.8 0.8 0.8 63±14 63±16 64±14 64±14 63±13 62±13 6 8 6 5 58 58 57 82 75 80 84 4 4 4 4 4 4 4 4 4 4 10-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 75 80 84 3 3 2 3</td></td>	2 963 176 594 877 (20) 767 468 (26) 76 (62–91) 80 (64–94) 76 (61–90) 77 81 77 15 13 15 6 5 6 2 1 2 0.8 0.7 0.8 63±14 63±16 64±14 6 8 6 56 54 57 82 75 80 14 22 1 4 4 4 1 (0–2) 1 (0–2) 1 (0–2) 7 6 7 10 9 9 3 4 3 18 19 19 3 4 3 27 20 24 12 12 13 18 19 19 3 4 3 27 20 24 12 14 13 <	2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 76 (62-91) 80 (64-94) 76 (61-90) 75 (61-89) 77 81 77 75 15 13 15 16 6 5 6 7 2 1 2 2 0.8 0.7 0.8 0.8 63±14 63±16 64±14 64±14 6 8 6 5 56 54 57 58 ***********************************	2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 368 272 (12) 76 (62-91) 80 (64-94) 76 (61-90) 75 (61-89) 75 (60-89) 77 81 77 75 75 15 13 15 16 16 6 5 6 7 7 2 1 2 2 2 0.8 0.7 0.8 0.8 0.8 63±14 63±16 64±14 64±14 63±13 6 8 6 5 5 56 54 57 58 58 82 75 80 84 85 14 22 16 13 11 4 3 4 4 4 10-2) 1(0-2) 1(0-2) 1(0-2) 7 6 7 7 7 10 10 10 10 9 9 9 9 <td>2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 368 272 (12) 228 243 (8) 76 (62-91) 80 (04-94) 76 (61-90) 75 (61-89) 75 (60-89) 75 (60-90) 77 81 77 75 75 75 75 15 13 15 16 16 15 6 5 6 7 7 7 2 1 2 2 2 2 0.8 0.7 0.8 0.8 0.8 0.8 63±14 63±16 64±14 64±14 63±13 62±13 6 8 6 5 58 58 57 82 75 80 84 4 4 4 4 4 4 4 4 4 4 10-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 75 80 84 3 3 2 3</td>	2 963 176 594 877 (20) 767 468 (26) 571 781 (19) 368 272 (12) 228 243 (8) 76 (62-91) 80 (04-94) 76 (61-90) 75 (61-89) 75 (60-89) 75 (60-90) 77 81 77 75 75 75 75 15 13 15 16 16 15 6 5 6 7 7 7 2 1 2 2 2 2 0.8 0.7 0.8 0.8 0.8 0.8 63±14 63±16 64±14 64±14 63±13 62±13 6 8 6 5 58 58 57 82 75 80 84 4 4 4 4 4 4 4 4 4 4 10-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 1(0-2) 75 80 84 3 3 2 3				

(Continued)

Table 2. Continued

		Baseline serum triglycerides group, mg/dL									
Characteristic	Total	<80	80-<120	120-<160	160-<200	200-<240	≥240				
BMI, kg/m ²	29±6	27±5	28±6	30±6	30±6	31±6	31±6				
Lipid panel, mg/dL		1			1	1	J				
Triglycerides	127 (87–189)	63 (53–72)	99 (89–109)	138 (128–148)	177 (168–188)	217 (208–228)	312 (268–395)				
HDL-C	42 (35–51)	51 (42–62)	45 (38–53)	41 (35–49)	39 (33–46)	38 (32–44)	36 (30-42)				
Cholesterol	178 (153–206)	164 (142–189)	172 (148–198)	178 (154–205)	184 (159–211)	188 (164–216)	202 (174–233)				
LDL-C	104 (83–129)	99 (79–120)	105 (85–129)	108 (86–133)	108 (86–134)	107 (84–133)	100 (75–129)				
Lipid-modulating therapy use,	%	1				1	1				
Statin	48	39	48	51	52	53	51				
Ezetimibe	1	1	1	1	1	1	1				
Nonstatin	9	4	6	8	10	13	21				
Fibrate	5	2	3	4	6	8	15				
Niacin	3	2	2	3	3	4	5				
Fish oil	0.3	0.1	0.2	0.3	0.4	0.5	0.8				
Bile acid sequestrants	1	1	1	1	1	1	1				

Data presented as mean±SD, median (interquartile range), or percentage as appropriate. ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CCI, Charlson comorbidity index; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HDL-C, high-density lipoprotein cholesterol; ISHD, ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PTSD, posttraumatic stress disorder; PVD, peripheral vascular disease; SBP, systolic blood pressure; and WBC, white blood cell.

*eGFR provided for only patients classified as CKD stage 5, yet not on ESRD.

⁺ Other race may include American Indian, Asian, Pacific Islander, multi-race and other race not included in White or Black categories.

an attenuated relationship between triglycerides and ASCVD hospitalization but still reflected that elevated triglycerides were associated with a higher risk of event except for in patients with CKD stage 5/ESRD (Figure S2). The triglycerides and non-ASCVD relationship was also attenuated and demonstrated that the non-ASCVD hospitalization risk diminished across CKD stages in patients with high triglycerides ≥240 mg/dL.




Figure 1. Association of baseline triglycerides with time to atherosclerotic cardiovascular disease (ASCVD) (A) and non-ASCVD (B) hospitalization across chronic kidney disease (CKD) stages after adjustment for case-mix+laboratory covariates. Model adjustments: age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of nonstatins, body mass index, and albumin. ESRD indicates end-stage renal disease.

Subgroup Analyses for Baseline Triglycerides With Time to Hospitalizations

Subgroup analyses reflected similar yet attenuated relationships across strata of age, diabetes, LDL-C levels, statin use, race, and prior CVD (Tables S5 and S6). In general, we observed that the association of high triglycerides ≥240 mg/dL with each outcome depicted a similar cascade across advancing CKD stages. Notably, high triglycerides levels were no longer associated with decreased time to non-ASCVD hospitalization among patients with CKD stage 5/ESRD and those aged <65 years. Among patients with LDL-C <100 mg/dL and CKD stage 5/ESRD, the associations of high triglycerides ≥240 mg/dL with ASCVD and non-ASCVD events were each strengthened to an almost 10% lower risk of event. Conversely, patients with high LDL-C ≥100 mg/dL, high triglycerides, and CKD stage 4 had a null relationship with ASCVD or non-ASCVD hospitalization, whereas a slightly higher risk was observed in patients with CKD stage 5/ESRD and high triglycerides. The relationship of triglycerides and non-ASCVD events among patients without prior CVD was largely flat, whereas the triglycerides-ASCVD relationship remained linear across prior CVD strata.

Association of Time-Varying Triglycerides With Time to Hospitalizations

We further explored the relationship of triglycerides with ASCVD and non-ASCVD hospitalizations using time-varying models (Tables S7 and S8 and Figure 2A and 2B). After adjustment for time-varying case-mix+laboratory covariates, low time-varying triglycerides were generally associated with a null or lower risk of ASCVD hospitalization across strata of baseline CKD stage (reference: triglycerides 120– <160 mg/dL). Time-varying triglycerides ≥240 mg/dL were associated with a higher risk of ASCVD hospitalization for baseline non-CKD and CKD stage 3A to 3B. Similar to the baseline analysis, we observed a cascade in effect estimates in the association of high time-varying triglycerides and ASCVD event, including a null association among those with CKD stage 4 and 5/ESRD.

Alternatively, the association of time-varying triglycerides with time to non-ASCVD event was inverse across baseline CKD stages. Time-varying triglycerides <120 mg/dL were associated with a higher risk of non-ASCVD hospitalization across baseline CKD stages, with the exception of patients with CKD stage 5/ ESRD in the case-mix+laboratory model. We observed a lower to null risk of non-ASCVD hospitalization for time-varying triglycerides ≥160 mg/dL across all CKD stages. Patients with baseline CKD stage 5/ESRD with the highest time-varying triglycerides ≥240 mg/dL had the lowest risk of non-ASCVD hospitalization (hazard ratio [95% CI], 0.86 [0.81–0.91]). Results were similar with time-updated lipid adjustment.

DISCUSSION

We evaluated long- and short-term associations between triglycerides and ASCVD and non-ASCVD hospitalization across CKD stages. Our observations suggest linear associations between baseline and




Figure 2. Association of time-varying triglycerides with time to atherosclerotic cardiovascular disease (ASCVD) (A) and non-ASCVD (B) hospitalization across baseline chronic kidney disease (CKD) stages after adjustment for case-mix+laboratory covariates.

Model adjustments: age, sex, race, ethnicity, ever smoker, ever alcoholism, time-updated Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of nonstatins, body mass index, albumin, and CKD stage. ESRD indicates end-stage renal disease.

time-varying triglycerides with ASCVD hospitalization across CKD stages. For non-ASCVD outcomes, the relationship with baseline triglycerides was U-shaped in CKD stage 3A and 3B patients, but the time-varying triglycerides relationship was inverse and linear for all CKD stages. Across all analyses, we observed a similar pattern: the relationship with elevated triglycerides with hospitalizations incrementally declined in the magnitude of risk across worsening CKD stages, where patients with advanced CKD (stage 4 and 5/ ESRD) tended to have null or lower associations with ASCVD and non-ASCVD hospitalizations.

Studies have examined the relationship of triglycerides with CVD events in patients with CKD, vet did not investigate relationships within individual CKD stages. The ARIC (Atherosclerosis Risk in Communities) study suggested that each quartile increase in triglycerides was associated with a higher risk of coronary heart disease among patients with CKD (eGFR 15-<60 mL/min per 1.73 m²), but included minimal adjustment.¹⁶ The MESA (Multi-Ethnic Study of Atherosclerosis) observed the potential interaction between patients without and with CKD (Pinteraction=0.07) for an SD increase of log triglycerides with coronary heart disease risk.¹⁵ Finally, the CRIC (Chronic Renal Insufficiency Cohort) study showed linear associations between triglycerides tertiles and ASCVD events among patients with CKD.¹³ However, they did not observe interaction by eGFR (<45 and ≥45 mL/min per 1.73 m²), where associations for triglycerides >160 mg/dL among each strata had a 24% to 25% higher risk of event (reference: trialycerides <103 mg/dL), and were attenuated. The magnitude of effect estimates from the CRIC study and MESA suggests a higher risk of ASCVD events with elevated triglycerides among patients with predominantly earlystage CKD. This was similarly observed in our patients with CKD 3A and 3B, where we had the power to examine individual stages and smaller clinically relevant groups of triglycerides.

A post hoc analysis of the SHARP (Study of Heart and Renal Protection) showed weak to null associations between higher trialycerides and ASCVD events, even when stratified at eGFR 30 mL/min per 1.73 m^{2.14} We also observed that patients with CKD stage 5/ ESRD had a null risk of ASCVD events, yet the SHARP analyses for patients with early-stage CKD not only contrasted our study, but also the CRIC study and MESA. Both the CRIC study and MESA comprised primarily patients with CKD stage 3A to 3B, and thus were limited in the evaluation of later stages. Although SHARP did investigate patients with late-stage CKD and dialysis, it also excluded patients with prior myocardial infarction, which may render these study participants less generalizable to the general population with CKD. Moreover, these studies were limited in their ability to account for confounders without overadjustment. Our data allowed for the adjustment of potential confounders, including comorbidities and markers of malnutrition and inflammation often absent from prior studies. Notably, we observed a higher risk of ASCVD events with high triglycerides (≥160 mg/dL) across non-CKD and CKD stages 3A to 4. Akin to SHARP, we observed an attenuated relationship with triglycerides and ASCVD outcomes in patients with CKD stage 5/ ESRD. These results were consistent with findings in patients undergoing hemodialysis, in whom elevated triglycerides levels were associated with lower risks of mortality and possibly attributable to the malnutrition and inflammation that are prevalent in this population.^{10,26}

Few studies have examined the relationship of triglycerides and non-ASCVD events. SHARP showed that triglycerides were not associated with higher risk of non-ASCVD events among those with early-stage CKD, whereas there was a lower risk of non-ASCVD events among late-stage CKD. In our baseline study, we observed an elevated risk of non-ASCVD events with high triglycerides among patients without CKD and patients with CKD stage 3A, whereas the risk was attenuated or lower in later stages. In our time-varying analyses, we observed a lower risk of non-ASCVD events with elevated triglycerides for all CKD stages. Within SHARP, it was suggested that the relationships may be attributable to inflammation and reverse causality.¹⁴ Specifically, our time-varying analyses included time-updated covariates to account for temporality. We also adjusted for albumin as a marker of inflammation, but we acknowledge the limitation that stronger markers of inflammation were unavailable in this cohort. Although most studies evaluating triglycerides have been in the context of ASCVD, future research will need to clarify the association of triglycerides with outcomes not related to ASCVD, especially in patients with CKD.

Clinical trials have suggested an important role of remnant cholesterol and triglyceride-rich lipoprotein in the development of ASCVD events.²⁷ The lipoprotein lipase that lies in the vascular endothelial surface can degrade the circulating triglycerides, thereby allowing remnant cholesterol and triglyceride-rich lipoprotein to be taken up by the arterial wall without the need of further oxidation.^{28,29} For non-ASCVD events, a similar explanation of triglyceride-rich lipoprotein accumulation in the arterial wall as well as in the heart muscle, leading to cardiomyopathy, has been suggested in prior studies evaluating triglycerides and heart failure. These studies suggested that associations may be explained by the proinflammatory and toxic role of triglycerides, yet further research is needed.^{23,30} Although these mechanisms may explain the relationships in patients with early-stage CKD, animal models have indicated that lipid metabolism is altered in advanced CKD stages.⁸ Prior studies primarily relied on baseline triglycerides measurement, even though lipid metabolism can become dysregulated through CKD progression, rendering the possibility of an altered impact over time as triglycerides levels change. Thus, a baseline triglycerides measurement in early-stage CKD may not fully capture the triglycerides-hospitalization relationship after transition to advanced CKD. Patients with CKD have a higher prevalence of hypertriglyceridemia, in part attributable to impaired clearance of lipoproteins in conjunction with reduced kidney function.^{31,32} Particularly in patients with advanced CKD, it may be that the greater prevalence of nontraditional risk factors, such as malnutrition, cachexia, and protein-energy wasting, become more prominent and dominate the triglyceride-rich lipoprotein relationship.^{23,30} Such conditions are associated with a disordered energy metabolism that explains why elevated triglycerides were not associated with ASCVD and non-ASCVD hospitalizations in later CKD stages, as demonstrated in this study. Moreover, clinical trials have noted that treatment with icosapent ethyl and statins was effective in lowering risks of ASCVD events in high-risk patients with established CVD or diabetes; however, these trials excluded patients with CKD stage 4 to 5 and those undergoing dialysis.³³ Thus, future studies, including clinical trials, are needed to better understand the effects of elevated triglycerides as well as the impact of pharmacologic treatments, particularly in patients with late-stage CKD, in whom nontraditional risk factors are more prevalent. Such studies will be informative in better tailoring clinical guidelines, including those describing lipid-lowering modulation therapies focused on this high-risk population.

Using our repeated measured data, we examined the time-varying relationships of triglycerides and hospitalizations, showing largely similar patterns with our baseline results. Yet, our non-ASCVD relationship had an inverse and linear pattern, suggesting that in the short-term, elevated triglycerides levels are not associated with a higher risk of non-ASCVD events in both patients without CKD and patients with CKD. To date, there is little information on the short-term risk of events with time-varying triglycerides and outcomes in patients with CKD. This observation of the lower risk of non-ASCVD events in the short-term for patients with advanced CKD further highlights the paradoxical relationships between lipids and outcomes, and merits additional investigation.¹¹

Highlighted strengths of this study include the large sample size, use of multiple sources of data, and length of follow-up, which lend the ability to evaluate CKD stages and time-varying triglycerides. Few studies have evaluated serial triglycerides measurements,

and our ability to examine short-term associations, especially as one progresses through CKD, is a strength of this study. In addition, we note several limitations. We were unable to adjust for potential confounders, such as diet, apolipoproteins, or other markers of inflammation, including CRP (C-reactive protein). Data on UACR were only available in a select population, yet analysis in this subgroup demonstrated similar but attenuated relationships. Our negative control analyses suggested that our results may be less subject to uncontrolled confounding.³⁴ We believe our triglycerides measurements were drawn after fasting given standard laboratory practice; however, we are unable to confirm fasting status. Prior studies have demonstrated small differences between fasting and nonfasting triglycerides levels, as well as the utility of nonfasting triglycerides in CVD risk prediction, yet we acknowledge that our results may be subject to misclassification.^{35–38} Moreover, we restricted our outcomes to primary or secondary ICD-9 codes to identify adverse events and minimize potential misclassification that stemmed from health administration medical records. Finally, our results may not be generalizable to the general population given that our source cohort is primarily composed of older White men.

In conclusion, we showed the short- and longterm associations of triglycerides with ASCVD and non-ASCVD hospitalizations across CKD stages. Relationships incrementally declined across worse CKD stages for elevated triglycerides, a known CVD risk factor. Given the burden and risk of CVD among patients with CKD, it is important to evaluate both the immediate and long-term impact of triglycerides on ASCVD and non-ASCVD events as to best manage cardiovascular health in this vulnerable population. Future studies as well as clinical trials are necessary to target and manage triglycerides, with a specific focus on patients with late-stage CKD.

ARTICLE INFORMATION

Received June 22, 2021; accepted October 12, 2021.

Affiliations

Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA; Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA (M.S., J.-T.H., H.M., K.K.-Z., E.S.); Department of General Internal Medicine, Greater Los Angeles Healthcare System, Los Angeles, CA (L.H.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA (L.H.); Department of General Internal Medicine, Greater Los Angeles, CA (L.H.); Department of General Internal Medicine, Greater Los Angeles, CA (L.H.); David Geffen School of Medicine, University of California Los Angeles, CA (L.H.); David Geffen School of Medicine, University of California Los Angeles, CA (L.H.); David Geffen School of Medicine, University of California Los Angeles, CA (M.J.B.); Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, TN (C.P.K.); and Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN (C.P.K.).

Sources of Funding

This study was supported by Dr Streja's Career Development Award IK2-CX 001266-01 from the US Veterans Administration Clinical Sciences Research and Development Program. The data reported herein have been supplied by the US Veterans Administration. Support for Veterans Affairs (VA)/Centers for Medicare and Medicaid Services data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project numbers SDR 02-237 and 98-004). Opinions expressed in this presentation are those of the authors and do not represent the official opinion of the US Department of Veterans Affairs or the US government. Dr Kalantar-Zadeh has been supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases midcareer award K24-DK091419. Dr Streja is supported by a career development award from the Office of Research and Development of the Department of Veterans Affairs (IK2- CX 001266-01). Dr Moradi is supported by a career development award from the Office of Research and Development of the Department of Veterans Affairs (1IK-CX 001043-01A2).

Disclosures

Dr Kalantar-Zadeh has received honoraria and/or support from Abbott, Abbvie, Alexion, Amgen, American Society of Nephrology, Astra-Zeneca, AVEO Oncology, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hofstra Medical School, International Federation of Kidney Foundations, International Society of Hemodialysis, International Society of Renal Nutrition & Metabolism, Japanese Society of Dialysis Therapy, Hospira, Kabi, Keryx, Novartis, National Institutes of Health, National Kidney Foundation, OPKO, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZSPharma. Dr Kovesdy has received honoraria from Abbott, Akebia, Astra-Zeneca, Bayer, Cara Therapeutics, Vifor, and Rockwell. Dr Moradi has received research funding from Novartis and Amgen. Dr Streja has received support from Astra Zeneca and Edwards Lifesciences.

Supplementary Material

Tables S1–S8 Figures S1–S2

REFERENCES

- Stauffer ME, Weisenfluh L, Morrison A. Association between triglycerides and cardiovascular events in primary populations: a metaregression analysis and synthesis of evidence. *Vasc Health Risk Manag.* 2013;9:671–680. doi: 10.2147/VHRM.S52713
- Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. *Lipids Health Dis.* 2013;12:159. doi: 10.1186/1476-511X-12-159
- Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. *Circ Cardiovasc Qual Outcomes.* 2016;9:100–108. doi: 10.1161/CIRCOUTCOM ES.115.002104
- Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. *Nat Rev Cardiol.* 2017;14:577–590. doi: 10.1038/nrcardio.2017.78
- Chawla V, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. *Clin J Am Soc Nephrol.* 2010;5:1582–1587. doi: 10.2215/ CJN.01450210
- United States Renal Data System. 2016 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2016.
- Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol metabolism in CKD. Am J Kidney Dis. 2015;66:1071–1082. doi: 10.1053/j.ajkd.2015.06.028
- Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am J Physiol Renal Physiol.* 2006;290:F262–F272. doi: 10.1152/ajprenal.00099.2005

- Choudhury D, Tuncel M, Levi M. Disorders of lipid metabolism and chronic kidney disease in the elderly. *Semin Nephrol.* 2009;29:610–620. doi: 10.1016/j.semnephrol.2009.07.006
- Soohoo M, Moradi H, Obi Y, Kovesdy CP, Kalantar-Zadeh K, Streja E. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. *J Clin Lipidol*. 2019;13:744–753.e15. doi: 10.1016/j.jacl.2019.08.001
- Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutritioninflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18:304– 311. doi: 10.1681/ASN.2006060674
- 12. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM. 2017;110:493–500. doi: 10.1093/gjmed/hcx040
- Bajaj A, Xie D, Cedillo-Couvert E, Charleston J, Chen J, Deo R, Feldman HI, Go AS, He J, Horwitz E, et al. Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD. *Am J Kidney Dis.* 2019;73:827–836. doi: 10.1053/j.ajkd.2018.11.010
- Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH; SHARP Collaborative Group. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. *Clin J Am Soc Nephrol.* 2020;15:47–60. doi: 10.2215/CJN.07320619
- Lamprea-Montealegre JA, McClelland RL, Grams M, Ouyang P, Szklo M, de Boer IH. Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. *Heart*. 2018;104:1455–1460. doi: 10.1136/heartjnl-2017-312794
- Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2005;16:529–538. doi: 10.1681/ASN.2004080656
- McGinnis KA, Brandt CA, Skanderson M, Justice AC, Shahrir S, Butt AA, Brown ST, Freiberg MS, Gibert CL, Goetz MB, et al. Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source. *Nicotine Tob Res.* 2011;13:1233–1239. doi: 10.1093/ ntr/ntr206
- VIReC. Calculating a comorbidity index for risk adjustment using VA or Medicare data. April 2014. Available at: https://vaww.virec.research. va.gov/Tutorials/CALC-CCI/Tutorial-CALC-CCI.pdf. Accessed June 8, 2017.
- Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. *Med Care.* 2006;44:921–928. doi: 10.1097/01. mlr.0000223480.52713.b9
- Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. *JAMA*. 2013;310:2061–2068. doi: 10.1001/ jama.2013.280532
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006
- Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, Gillen D, Pahl MV, Vaziri ND, Kalantar-Zadeh K. Association of serum lipids with outcomes in Hispanic hemodialysis patients of the West versus East Coasts of the United States. *Am J Nephrol.* 2015;41:284–295. doi: 10.1159/00038 1991
- Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dl) and high triglycerides (200–499 mg/dl) are significant predictors of new heart failure diagnosis: a real-world analysis of high-risk statin-treated patients. *Vasc Health Risk Manag.* 2019;15:533–538. doi: 10.2147/VHRM.S221289
- Lee Y, Park S, Lee S, Kim Y, Kang MW, Cho S, Park S, Han K, Kim YC, Han SS, et al. Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: a nationwide population-based study. *PLoS One.* 2020;15:e0231328. doi: 10.1371/journal.pone.0231328
- Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. doi: 10.1080/01621 459.1999.10474144
- Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303. doi: 10.1681/ASN.2006070795

- Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–635. doi: 10.1016/S0140-6736(14)61177-6
- Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171–183. doi: 10.2147/ VHRM.S104369
- Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappiè S, Catapano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. *J Clin Endocrinol Metab.* 2004;89:2946–2950. doi: 10.1210/jc.2003-031977
- Varbo A, Nordestgaard BG. Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: two cohort studies of 113 554 individuals. *Arterioscler Thromb Vasc Biol.* 2018;38:464–472. doi: 10.1161/ATVBAHA.117.310269
- Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, Watts GF. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. *J Lipid Res.* 2009;50:2524–2531. doi: 10.1194/jlr.P900003-JLR200
- Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. *Curr Opin Lipidol.* 2015;26:56–63. doi: 10.1097/MOL.000000000000146
- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular risk

reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med.* 2019;380:11–22. doi: 10.1056/NEJMoa1812792

- Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology*. 2010;21:383–388. doi: 10.1097/EDE.0b013e3181d61eeb
- Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA*. 2007;298:309–316. doi: 10.1001/ jama.298.3.309
- Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation*. 2008;118:993–1001. doi: 10.1161/CIRCULATIO NAHA.108.777334
- Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation*. 2008;118:2047– 2056. doi: 10.1161/CIRCULATIONAHA.108.804146
- Eberly LE, Stamler J, Neaton JD; Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. *Arch Intern Med.* 2003;163:1077–1083. doi: 10.1001/archinte.163.9.1077

SUPPLEMENTAL MATERIAL

 Table S1. Comparison of Characteristics Between Patients with and without data on UACR.

	Without UACR	With UACR	Std. Diff
N(%)	2,768,375(93%)	194,801(7%)	
eGFR(mL/min/1.73m ²)	77[62,91]	72[56,87]	-0.24
CKD Stage (%)	77	69	-0.19
Non-CKD	14	19	0.12
СКД ЗА	6	9	0.12
CKD 3B	2	2	0.05
CKD 4	0.8	0.6	-0.02
CKD 5/ESRD	77	69	-0.19
Serum Triglycerides Group (mg/dL)		0,7	0.17
<80	20	15	
80-<120	26	23	
120-<160	19	20	0.18
160-<200	12	14	0.10
200-<240	8	9	
≥240	14	19	
Age (years)	63±14	66±11	0.28
Sex (% Female)	6	3	-0.16
Married(%)	56	58	0.04
Race(%)	30	30	0.04
White	82	81	-0.01
	14	14	
African American		5	-0.01
Other	4 4	<u> </u>	0.05
Hispanic Ethnicity(%)			0.02
CCI	1[0,2]	2[1,3]	0.56
Comorbid Conditions (%)		0	0.00
MI	6	9	0.08
CHF	10	15	0.15
PVD	9	14	0.14
Cerebrovascular Disease	9	11	0.08
Dementia	3	2	-0.03
COPD	18	19	0.03
Liver Disease	3	3	0.00
Diabetes	23	88	1.73
Cancer	12	13	0.03
Anemia	11	15	0.10
Atrial Fibrillation	7	8	0.05
Hypertension	62	85	0.55
ISHD	26	38	0.25
Depression	18	19	0.03
Anxiety	12	13	0.02
PTSD	7	9	0.05
Gallbladder Disease	0.4	0.5	0.01
Ever Smoking	64	65	0.02
Ever Alcoholism	26	16	-0.25
Laboratory Measurements			
Albumin (g/dL)	4.1±0.4	4.0±0.4	-0.16
AST(U/L)	23[19,29]	22[18,28]	-0.07
ALT (U/L)	25[18,35]	25[18,35]	-0.04
Glucose (mg/dL)	112.3±39.2	144.6±55.7	0.67

Hemoglobin (g/dL)	14.5±1.6	14.0±1.7	-0.31
WBC (x 10 ³ /mm ³)	7.2±2.7	7.3±2.8	0.06
SBP (mmHg)	135±18	135±17	0.04
DBP (mmHg)	76±11	73±11	-0.25
BMI (kg/m ²)	29±6	31±6	0.38
Lipid Panel (mg/dL)			
Triglycerides	126[86,187]	143[97,213]	0.16
HDL	42[35,52]	39[33,46]	-0.32
Cholesterol	179[154,207]	164[142,190]	-0.34
LDL	105[84,130]	91[73,112]	-0.40
Lipid Modulating Therapy Use(%)			
Statin	46	69	0.46
Ezetimibe	1	2	0.08
Non-statin	9	17	0.26
Fibrate	5	11	0.22
Niacin	3	5	0.11
Fish Oil	0.3	0.8	0.06
Bile Acid Sequestrants	1	1	0.05

Data presented as mean \pm standard deviation, median[interquartile range], or percentage, as appropriate. Standardized differences of ≥ 0.2 are considered as a meaningful imbalance, where 0.8, 0.5 and 0.2 represent large, medium and small imbalances, respectively.

ALT; Alanine Aminotransferase, AST; Aspartate Aminotransferase, BMI; Body Mass Index, CCI; Charlson Comorbidity Index, CHF; Congestive Heart Failure, CKD; Chronic Kidney Disease, COPD; Chronic Obstructive Pulmonary Disorder, DBP; Diastolic Blood Pressure, eGFR; estimated glomerular filtration rate, ESRD; end-stage renal disease, HDL; High Density Lipoprotein, ISHD; Ischemic Heart Disease, LDL; Low Density Lipoprotein, MI; Myocardial Infarction, PTSD; Post-traumatic Stress Disorder, PVD; Peripheral Vascular Disease, SBP; Systolic Blood Pressure, WBC; White Blood Cells Count, UACR; urine albumin-to-creatinine ratio *eGFR provided for only patients classified as CKD stage 5, yet not on ESRD.

	ASCVD Hospitalization											
Stage		Total	N	on-CKD	CKD Stage 3A		CKD Stage 3B		CK	CD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]
<80	126034	30.7 [30.5,30.8]	85532	24.4 [24.2,24.5]	25567	58.8 [58.1,59.5]	10851	84.7 [83.1,86.3]	2563	113.6 [109.3,118.1]	1521	120.4 [114.5,126.6]
80-<120	191356	36.2 [36.1,36.4]	124207	28.8 [28.6,28.9]	41321	60.4 [59.8,61.0]	18671	84.7 [83.5,85.9]	4741	113.0 [109.9,116.3]	2416	116.1 [111.5,120.8]
120-<160	151690	38.2 [38.0,38.3]	96481	30.2 [30.0,30.4]	33106	61.5 [60.8,62.1]	16112	86.6 [85.3,88.0]	4093	113.0 [109.6,116.5]	1898	117.0 [111.9,122.4]
160-<200	100656	39.0 [38.8,39.2]	63987	30.9 [30.7,31.2]	21522	60.9 [60.1,61.7]	11035	89.4 [87.8,91.1]	2837	117.4 [113.2,121.8]	1275	113.0 [107.0,119.4]
200-<240	63726	39.7 [39.4,40.0]	40556	31.5 [31.2,31.8]	13509	62.6 [61.6,63.7]	6948	88.4 [86.4,90.5]	1874	118.1 [112.9,123.6]	839	116.9 [109.2,125.1]
≥240	123455	40.4 [40.2,40.6]	80426	32.3 [32.1,32.5]	24557	65.3 [64.5,66.1]	13169	92.4 [90.9,94.0]	3768	119.0 [115.2,122.8]	1535	104.9 [99.8,110.3]
Total	756917	36.7 [36.6,36.8]	491189	29.1 [29.0,29.2]	159582	61.3 [61.0,61.6]	76786	87.4 [86.7,88.0]	19876	115.3 [113.7,116.9]	9484	114.6 [112.3,116.9]
					Non-A	SCVD Hospitaliz						
Stage		Total	N	on-CKD	CKD Stage 3A CKD Stage 3B			CK	XD Stage 4	CKD	Stage 5/ESRD	
Serum Triglycerides Group (mg/dL)	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]	N Event	Rate per 1000 person-years [95% CI]
<80	181246	45.9 [45.7,46.1]	120552	35.4 [35.2,35.6]	36378	90.0 [89.0,90.9]	16913	150.4 [148.2,152.7]	4576	265.5 [257.9,273.3]	2827	358.0 [345.0,371.4]
80-<120	249345	48.7 [48.5,48.9]	156258	36.9 [36.8,37.1]	54240	83.8 [83.1,84.5]	26760	135.0 [133.4,136.6]	7772	232.7 [227.6,238.0]	4315	323.0 [313.5,332.8]
120-<160	187912	48.4 [48.1,48.6]	115282	36.5 [36.3,36.7]	41232	79.5 [78.7,80.2]	21842	129.1 [127.4,130.8]	6371	216.4 [211.2,221.8]	3185	297.0 [286.9,307.5]
160-<200	121012	47.7 [47.5,48.0]	74035	36.0 [35.8,36.3]	26385	77.4 [76.5,78.3]	14313	126.0 [124.0,128.1]	4211	212.0 [205.7,218.5]	2068	266.7 [255.4,278.4]
200-<240	74092	46.6 [46.3,46.9]	45102	35.0 [34.7,35.4]	15952	75.6 [74.4,76.8]	9000	122.6 [120.1,125.2]	2712	206.5 [198.9,214.4]	1326	264.5 [250.7,279.1]
≥240	138752	45.6 [45.4,45.9]	86133	34.4 [34.2,34.7]	28258	76.4 [75.6,77.3]	16502	124.0 [122.1,125.9]	5442	210.2 [204.6,215.8]	2417	238.9 [229.5,248.6]
Total	952359	47.3 [47.2,47.4]	597362	35.9 [35.8,36.0]	202445	81.2 [80.9,81.6]	105330	131.7 [130.9,132.5]	31084	223.7 [221.2,226.2]	16138	294.1 [289.6,298.7]

Table S2. ASCVD and non-ASCVD Incident Hospitalization Event Rates Stratified by Baseline Serum Triglycerides andBaseline CKD Stage.

_					djusted					
Stage	I	Non-CKD	CK	CD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.81[0.80,0.81]	<.0001	0.95[0.94,0.97]	0.01	0.97[0.95,0.99]	0.78	0.99[0.95,1.04]	0.98	1.00[0.94,1.07]
80-<120	<.0001	0.95[0.95,0.96]	0.01	0.98[0.97,1.00]	0.02	0.98[0.95,1.00]	0.79	0.99[0.95,1.04]	0.61	0.98[0.93,1.05]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.03[1.02,1.04]	0.44	0.99[0.98,1.01]	0.01	1.03[1.01,1.06]	0.11	1.04[0.99,1.09]	0.44	0.97[0.91,1.04]
200-<240	<.0001	1.04[1.03,1.06]	0.05	1.02[1.00,1.04]	0.13	1.02[0.99,1.05]	0.08	1.05[0.99,1.11]	0.93	1.00[0.93,1.09]
≥240	<.0001	1.07[1.06,1.08]	<.0001	1.06[1.05,1.08]	<.0001	1.07[1.05,1.09]	0.01	1.06[1.01,1.11]	0.01	0.92[0.86,0.98]
			_	Age	Adjusted					
Stage	1	Non-CKD	СК	D Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.79[0.78,0.79]	<.0001	0.90[0.89,0.91]	<.0001	0.94[0.92,0.97]	0.43	0.98[0.93,1.03]	0.48	0.98[0.91,1.04]
80-<120	<.0001	0.91[0.91,0.92]	<.0001	0.95[0.94,0.96]	0.0001	0.96[0.94,0.98]	0.50	0.99[0.95,1.03]	0.23	0.96[0.91,1.02]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.08[1.07,1.09]	0.004	1.03[1.01,1.04]	0.0002	1.05[1.02,1.07]	0.04	1.05[1.00,1.10]	0.77	0.99[0.92,1.06]
200-<240	<.0001	1.15[1.14,1.16]	<.0001	1.09[1.07,1.11]	0.002	1.05[1.02,1.08]	0.01	1.07[1.02,1.13]	0.37	1.04[0.96,1.13]
≥240	<.0001	1.33[1.32,1.34]	<.0001	1.20[1.19,1.23]	<.0001	1.13[1.11,1.16]	<.0001	1.12[1.07,1.17]	0.84	1.01[0.94,1.08]
				Case-M	ix Adjuste	ed				
Stage	1	Non-CKD	CK	CD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD Stage 5/ESRD	
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.88[0.87,0.89]	<.0001	0.95[0.94,0.97]	0.01	0.97[0.94,0.99]	0.64	1.01[0.96,1.06]	0.76	0.99[0.92,1.06]
80-<120	<.0001	0.96[0.95,0.96]	0.0001	0.97[0.96,0.99]	0.004	0.97[0.95,0.99]	0.64	0.99[0.95,1.03]	0.18	0.96[0.90,1.02]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.04[1.03,1.05]	0.10	1.02[1.00,1.03]	0.01	1.04[1.01,1.06]	0.18	1.03[0.99,1.08]	0.96	1.00[0.93,1.07]
200-<240	<.0001	1.09[1.08,1.10]	<.0001	1.05[1.03,1.07]	0.06	1.03[1.00,1.06]	0.26	1.03[0.98,1.09]	0.49	1.03[0.95,1.12]
≥240	<.0001	1.19[1.18,1.20]	<.0001	1.12[1.10,1.14]	<.0001	1.08[1.06,1.11]	0.01	1.06[1.02,1.11]	0.10	0.94[0.88,1.01]
	T		1	Case-Mix+			n			
Stage	1	Non-CKD	D CKD Stage 3A CKD Stage 3B CKD Stage 4			KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.84[0.83,0.85]	<.0001	0.91[0.89,0.92]	<.0001	0.93[0.90,0.95]	0.31	0.97[0.93,1.02]	0.14	0.95[0.89,1.02]
80-<120	<.0001	0.94[0.93,0.95]	<.0001	0.95[0.94,0.97]	<.0001	0.95[0.93,0.97]	0.13	0.97[0.93,1.01]	0.09	0.95[0.89,1.01]

 Table S3. Hazard Ratios for the Association of Baseline Serum Triglycerides with Time to ASCVD Hospitalization Stratified

 by Baseline CKD Stage across levels of adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.06[1.05,1.07]	0.002	1.03[1.01,1.05]	<.0001	1.05[1.02,1.08]	0.09	1.04[0.99,1.09]	0.46	1.03[0.96,1.10]
200-<240	<.0001	1.11[1.10,1.12]	<.0001	1.07[1.05,1.09]	0.001	1.05[1.02,1.08]	0.05	1.06[1.00,1.12]	0.14	1.06[0.98,1.15]
≥240	<.0001	1.22[1.21,1.23]	<.0001	1.15[1.13,1.17]	<.0001	1.11[1.09,1.14]	<.0001	1.10[1.05,1.15]	0.83	0.99[0.93,1.06]
				Case-Mix+La	b+Lipid A	djusted				
Stage	1	Non-CKD	CK	CD Stage 3A	CK	CD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.90[0.89,0.91]	<.0001	0.96[0.94,0.97]	0.01	0.97[0.94,0.99]	0.40	1.02[0.97,1.08]	0.59	0.98[0.91,1.05]
80-<120	<.0001	0.96[0.95,0.97]	<.0001	0.97[0.96,0.98]	0.002	0.97[0.95,0.99]	0.47	0.99[0.94,1.03]	0.22	0.96[0.91,1.02]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.05[1.04,1.06]	0.04	1.02[1.00,1.04]	0.001	1.04[1.02,1.07]	0.25	1.03[0.98,1.08]	0.59	1.02[0.95,1.10]
200-<240	<.0001	1.10[1.08,1.11]	<.0001	1.06[1.04,1.08]	0.01	1.04[1.01,1.07]	0.20	1.04[0.98,1.10]	0.24	1.05[0.97,1.14]
≥240	<.0001	1.21[1.20,1.22]	<.0001	1.14[1.12,1.16]	<.0001	1.10[1.08,1.13]	0.001	1.08[1.03,1.13]	0.48	0.98[0.91,1.05]

Model Adjustments:

Unadjusted

Age Adjusted: age

Case-Mix Adjusted: age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins

Case-Mix+Lab Adjusted: Case-Mix covariates and body mass index and albumin

Case-Mix+Lab+Lipid Adjusted: Case-Mix+Lab covariates and HDL and LDL cholesterols

		Stage act o		0	djusted					
Stage	ľ	Non-CKD	СК	CD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.97[0.96,0.98]	<.0001	1.13[1.11,1.14]	<.0001	1.15[1.13,1.18]	<.0001	1.20[1.16,1.25]	<.0001	1.15[1.09,1.21]
80-<120	0.005	1.01[1.00,1.02]	<.0001	1.05[1.04,1.07]	<.0001	1.04[1.02,1.06]	0.0002	1.07[1.03,1.10]	0.01	1.07[1.02,1.12]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.01	0.99[0.98,1.00]	0.002	0.98[0.96,0.99]	0.05	0.98[0.96,1.00]	0.38	0.98[0.95,1.02]	0.01	0.93[0.88,0.98]
200-<240	<.0001	0.96[0.95,0.97]	<.0001	0.95[0.94,0.97]	0.0002	0.95[0.93,0.98]	0.07	0.96[0.92,1.00]	0.01	0.92[0.86,0.98]
≥240	<.0001	0.95[0.94,0.95]	<.0001	0.96[0.95,0.98]	0.0006	0.97[0.95,0.99]	0.20	0.98[0.94,1.01]	<.0001	0.84[0.80,0.89]
				Age A	Adjusted					
Stage	Non-CKD CKD Stage 3A CKD Stage 3B CKD Stage 4							CKD	Stage 5/ESRD	
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.95[0.95,0.96]	<.0001	1.05[1.04,1.06]	<.0001	1.12[1.09,1.14]	<.0001	1.19[1.15,1.24]	<.0001	1.13[1.08,1.19]
80-<120	<.0001	0.97[0.96,0.98]	0.20	1.01[1.00,1.02]	0.02	1.02[1.00,1.04]	0.001	1.06[1.03,1.10]	0.02	1.06[1.01,1.10]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.04[1.03,1.05]	0.05	1.02[1.00,1.03]	0.71	1.00[0.98,1.02]	0.57	0.99[0.95,1.03]	0.01	0.93[0.88,0.98]
200-<240	<.0001	1.06[1.05,1.07]	0.001	1.03[1.01,1.05]	0.17	0.98[0.96,1.01]	0.19	0.97[0.93,1.02]	0.04	0.94[0.88,1.00]
≥240	<.0001	1.17[1.16,1.18]	<.0001	1.12[1.11,1.14]	0.0002	1.04[1.02,1.06]	0.80	1.01[0.97,1.04]	<.0001	0.88[0.84,0.93]
				Case-M	ix Adjuste					
Stage	I	Non-CKD	СК	D Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD Stage 5/ESRD	
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.79	1.00[0.99,1.01]	<.0001	1.07[1.05,1.08]	<.0001	1.08[1.06,1.11]	<.0001	1.15[1.11,1.19]	0.001	1.09[1.04,1.15]
80-<120	0.09	0.99[0.99,1.00]	0.002	1.02[1.01,1.03]	0.10	1.02[1.00,1.03]	0.01	1.04[1.01,1.08]	0.10	1.04[0.99,1.09]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.001	1.02[1.01,1.03]	0.49	1.01[0.99,1.02]	0.15	0.99[0.96,1.01]	0.66	0.99[0.95,1.03]	0.22	0.97[0.91,1.02]
200-<240	0.004	1.02[1.01,1.03]	1.00	1.00[0.98,1.02]	0.02	0.97[0.95,0.99]	0.001	0.93[0.88,0.97]	0.16	0.96[0.90,1.02]
≥240	<.0001	1.08[1.07,1.08]	<.0001	1.05[1.03,1.06]	0.49	0.99[0.97,1.01]	0.04	0.96[0.93,1.00]	<.0001	0.88[0.84,0.93]
Case-Mix+Lab Adjusted										
Stage	I	Non-CKD CKD Stage 3A CKD Stage 3B CKD Stage 4				KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.97	1.00[0.99,1.01]	<.0001	1.05[1.03,1.06]	<.0001	1.05[1.03,1.07]	<.0001	1.10[1.06,1.14]	0.14	1.04[0.99,1.10]
80-<120	0.07	0.99[0.99,1.00]	0.05	1.01[1.00,1.03]	0.79	1.00[0.99,1.02]	0.32	1.02[0.98,1.05]	0.15	1.03[0.99,1.08]

 Table S4. Hazard Ratios for the Association of Baseline Serum Triglycerides with Time to Non-ASCVD Hospitalization

 Stratified by Baseline CKD Stage across levels of adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.001	1.02[1.01,1.03]	0.18	1.01[1.00,1.03]	0.69	1.00[0.98,1.02]	0.97	1.00[0.96,1.04]	0.75	1.01[0.95,1.07]
200-<240	0.001	1.02[1.01,1.03]	0.34	1.01[0.99,1.03]	0.30	0.99[0.96,1.01]	0.02	0.95[0.91,0.99]	0.97	1.00[0.94,1.07]
≥240	<.0001	1.08[1.07,1.09]	<.0001	1.06[1.04,1.08]	0.1184	1.02[1.00,1.04]	0.74	0.99[0.96,1.03]	0.04	0.94[0.89,1.00]
				Case-Mix+La	b+Lipid A	djusted				
Stage	1	Non-CKD	CK	XD Stage 3A	CK	CD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.001	0.99[0.98,0.99]	<.0001	1.04[1.03,1.06]	<.0001	1.05[1.03,1.07]	<.0001	1.10[1.05,1.14]	0.15	1.04[0.99,1.10]
80-<120	0.002	0.99[0.98,1.00]	0.08	1.01[1.00,1.03]	0.91	1.00[0.98,1.02]	0.33	1.02[0.98,1.05]	0.15	1.04[0.99,1.08]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.0001	1.02[1.01,1.03]	0.16	1.01[1.00,1.03]	0.74	1.00[0.98,1.02]	0.96	1.00[0.96,1.04]	0.75	1.01[0.95,1.07]
200-<240	<.0001	1.02[1.01,1.03]	0.31	1.01[0.99,1.03]	0.34	0.99[0.96,1.01]	0.02	0.95[0.91,0.99]	0.99	1.00[0.94,1.07]
≥240	<.0001	1.08[1.07,1.09]	<.0001	1.06[1.04,1.08]	0.12	1.02[1.00,1.04]	0.69	0.99[0.96,1.03]	0.01	0.93[0.88,0.98]

Model Adjustments:

Unadjusted

Age Adjusted: age

Case-Mix Adjusted: age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins

Case-Mix+Lab Adjusted: Case-Mix covariates and body mass index and albumin

Case-Mix+Lab+Lipid Adjusted: Case-Mix+Lab covariates and HDL and LDL cholesterols

				Age<65 year	s (N =1,59	4,293)				
Stage	l	Non-CKD	CK	XD Stage 3A	Ck	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.80[0.79,0.81]	<.0001	0.84[0.80,0.89]	0.29	0.95[0.87,1.05]	0.98	1.00[0.86,1.17]	0.41	0.96[0.86,1.07]
80-<120	<.0001	0.93[0.92,0.94]	0.01	0.94[0.91,0.99]	0.89	0.99[0.92,1.08]	0.63	1.03[0.91,1.17]	0.47	0.97[0.88,1.06]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.07[1.05,1.09]	0.18	1.03[0.99,1.08]	0.003	1.13[1.04,1.22]	0.16	1.10[0.96,1.26]	0.30	1.06[0.95,1.18]
200-<240	<.0001	1.12[1.10,1.14]	0.01	1.07[1.01,1.12]	0.01	1.12[1.03,1.22]	0.08	1.14[0.98,1.31]	0.03	1.14[1.01,1.29]
≥240	<.0001	1.23[1.22,1.25]	<.0001	1.18[1.13,1.22]	<.0001	1.19[1.11,1.28]	0.01	1.16[1.04,1.30]	0.83	1.01[0.92,1.12]
				Age ≥65 year	rs (N =1,36	58,883)				
Stage	1	Non-CKD	CK	AD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.88[0.87,0.89]	<.0001	0.92[0.90,0.94]	<.0001	0.93[0.90,0.95]	0.25	0.97[0.92,1.02]	0.14	0.94[0.86,1.02]
80-<120	<.0001	0.95[0.94,0.96]	<.0001	0.96[0.94,0.97]	<.0001	0.95[0.93,0.97]	0.08	0.96[0.92,1.01]	0.12	0.94[0.87,1.02]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.04[1.02,1.05]	0.01	1.02[1.01,1.04]	0.003	1.04[1.01,1.07]	0.20	1.03[0.98,1.09]	0.93	1.00[0.91,1.10]
200-<240	<.0001	1.08[1.06,1.10]	<.0001	1.07[1.04,1.09]	0.01	1.04[1.01,1.07]	0.17	1.04[0.98,1.11]	0.81	1.01[0.91,1.13]
≥240	<.0001	1.16[1.14,1.17]	<.0001	1.13[1.11,1.16]	<.0001	1.10[1.08,1.13]	0.001	1.09[1.04,1.15]	0.57	0.97[0.88,1.07]
	-			Non-Diabetic		1 1	-		-	
Stage	1	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.84[0.83,0.85]	<.0001	0.90[0.89,0.92]	<.0001	0.92[0.89,0.95]	0.24	0.96[0.89,1.03]	0.003	0.84[0.75,0.94]
80-<120	<.0001	0.94[0.93,0.95]	<.0001	0.96[0.94,0.97]	0.0002	0.95[0.92,0.98]	0.55	1.02[0.96,1.08]	0.49	0.97[0.87,1.07]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.06[1.04,1.07]	0.15	1.02[0.99,1.04]	0.001	1.06[1.03,1.10]	0.03	1.08[1.01,1.17]	0.24	1.08[0.95,1.22]
200-<240	<.0001	1.11[1.09,1.13]	<.0001	1.07[1.04,1.10]	0.0004	1.08[1.03,1.12]	0.20	1.06[0.97,1.15]	0.07	1.14[0.99,1.31]
≥240	<.0001	1.20[1.19,1.22]	<.0001	1.14[1.11,1.16]	<.0001	1.09[1.06,1.13]	0.01	1.10[1.03,1.19]	0.54	0.96[0.85,1.09]
	1		1	Diabetics			1		1	
Stage	1	Non-CKD	CK	D Stage 3A	CK	CKD Stage 3B CKD Stage 4		CKD	Stage 5/ESRD	
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.83[0.82,0.85]	<.0001	0.91[0.89,0.94]	<.0001	0.92[0.89,0.96]	0.81	0.99[0.92,1.06]	0.88	1.01[0.93,1.10]
80-<120	<.0001	0.93[0.92,0.95]	<.0001	0.95[0.92,0.97]	0.004	0.95[0.92,0.99]	0.01	0.92[0.87,0.98]	0.08	0.94[0.87,1.01]

Table S5. Association of Baseline Serum Triglycerides with Time to ASCVD Hospitalization across Strata under Case-Mix + Lab adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.06[1.04,1.08]	0.00	1.04[1.01,1.07]	0.03	1.04[1.00,1.08]	0.63	1.02[0.95,1.08]	0.89	1.01[0.92,1.10]
200-<240	<.0001	1.11[1.09,1.13]	<.0001	1.07[1.04,1.10]	0.16	1.03[0.99,1.07]	0.15	1.05[0.98,1.13]	0.59	1.03[0.93,1.14]
≥240	<.0001	1.21[1.20,1.23]	<.0001	1.15[1.12,1.18]	<.0001	1.12[1.09,1.16]	0.01	1.09[1.03,1.15]	0.89	0.99[0.92,1.08]
				LDL <100 mg/	dL (N =1,	300,948)				
Stage	ľ	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.87[0.86,0.89]	<.0001	0.94[0.92,0.96]	<.0001	0.93[0.90,0.96]	0.54	1.02[0.96,1.08]	0.53	0.97[0.90,1.06]
80-<120	<.0001	0.95[0.94,0.96]	0.0001	0.96[0.94,0.98]	<.0001	0.95[0.92,0.97]	0.48	1.02[0.97,1.08]	0.54	0.98[0.91,1.05]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.04[1.03,1.06]	0.15	1.02[0.99,1.04]	0.05	1.03[1.00,1.07]	0.02	1.08[1.01,1.15]	0.72	1.02[0.93,1.11]
200-<240	<.0001	1.08[1.06,1.10]	0.02	1.03[1.01,1.06]	0.02	1.04[1.01,1.08]	0.04	1.08[1.00,1.16]	0.23	1.07[0.96,1.19]
≥240	<.0001	1.18[1.16,1.20]	<.0001	1.13[1.10,1.16]	<.0001	1.12[1.09,1.16]	<.0001	1.16[1.10,1.23]	0.11	0.93[0.85,1.02]
				LDL ≥100 mg/	dL (N = 1,	608,920)				
Stage	I	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.82[0.81,0.83]	<.0001	0.88[0.86,0.90]	0.002	0.94[0.90,0.98]	0.13	0.93[0.85,1.02]	0.02	0.84[0.73,0.97]
80-<120	<.0001	0.93[0.92,0.95]	<.0001	0.95[0.93,0.97]	0.06	0.97[0.94,1.00]	0.005	0.90[0.84,0.97]	0.02	0.88[0.78,0.98]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.07[1.05,1.08]	0.004	1.04[1.01,1.07]	0.001	1.07[1.03,1.11]	0.52	0.98[0.90,1.05]	0.59	1.03[0.92,1.17]
200-<240	<.0001	1.14[1.12,1.16]	<.0001	1.11[1.08,1.15]	0.01	1.06[1.02,1.11]	0.72	1.02[0.93,1.11]	0.58	1.04[0.91,1.19]
≥240	<.0001	1.26[1.25,1.28]	<.0001	1.19[1.15,1.22]	<.0001	1.10[1.06,1.15]	0.89	1.00[0.92,1.07]	0.11	1.10[0.98,1.23]
				No Statin Prescri	ption (N =	1,466,566)			/	
Stage	1	Non-CKD	CK	AD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.83[0.81,0.84]	<.0001	0.89[0.86,0.91]	<.0001	0.92[0.88,0.96]	0.33	0.96[0.88,1.05]	0.05	0.90[0.81,1.00]
80-<120	<.0001	0.94[0.92,0.95]	<.0001	0.95[0.92,0.97]	0.04	0.96[0.92,1.00]	0.62	0.98[0.91,1.06]	0.02	0.88[0.80,0.98]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	<.0001	1.07[1.05,1.08]	0.02	1.04[1.01,1.07]	0.12	1.04[0.99,1.09]	0.15	1.07[0.98,1.17]	0.73	0.98[0.87,1.10]
200-<240	<.0001	1.12[1.10,1.14]	<.0001	1.08[1.04,1.12]	0.32	1.03[0.97,1.08]	0.74	1.02[0.92,1.13]	0.45	1.06[0.92,1.21]
≥240	<.0001	1.23[1.21,1.25]	<.0001	1.15[1.11,1.18]	<.0001	1.12[1.07,1.17]	<.0001	1.18[1.09,1.28]	0.09	0.90[0.80,1.02]
				Statin Prescript	tion $(N = 1)$,353,351)				
Stage	I	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.86[0.85,0.87]	<.0001	0.92[0.91,0.94]	<.0001	0.93[0.91,0.96]	0.61	0.98[0.93,1.05]	0.63	0.98[0.89,1.07]

80-<120	<.0001	0.95[0.94,0.96]	<.0001	0.96[0.94,0.98]	<.0001	0.95[0.92,0.97]	0.12	0.96[0.91,1.01]	0.69	0.99[0.91,1.06]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	<.0001	1.05[1.03,1.06]	0.05	1.02[1.00,1.04]	0.0003	1.06[1.03,1.09]	0.29	1.03[0.97,1.09]	0.28	1.05[0.96,1.15]		
200-<240	<.0001	1.09[1.08,1.11]	<.0001	1.06[1.03,1.09]	0.001	1.06[1.02,1.09]	0.06	1.06[1.00,1.14]	0.22	1.07[0.96,1.18]		
≥240	<.0001	1.18[1.17,1.19]	<.0001	1.14[1.12,1.17]	<.0001	1.11[1.08,1.14]	0.06	1.05[1.00,1.11]	0.43	1.04[0.95,1.13]		
No Prior CVD (N = 2,070,569)												
Stage	ľ	Non-CKD	CK	XD Stage 3A	CK	CD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]		
<80	<.0001	0.81[0.80,0.83]	<.0001	0.86[0.84,0.89]	<.0001	0.90[0.85,0.94]	0.00	0.82[0.74,0.92]	0.15	0.91[0.79,1.04]		
80-<120	<.0001	0.93[0.92,0.94]	<.0001	0.93[0.91,0.96]	0.01	0.95[0.91,0.99]	0.00	0.88[0.81,0.96]	0.01	0.86[0.76,0.97]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	<.0001	1.07[1.05,1.09]	0.04	1.03[1.00,1.06]	0.01	1.06[1.02,1.12]	0.07	1.10[0.99,1.21]	0.26	0.92[0.80,1.06]		
200-<240	<.0001	1.14[1.12,1.16]	<.0001	1.08[1.04,1.11]	0.01	1.08[1.02,1.14]	0.43	1.05[0.94,1.17]	0.69	1.03[0.89,1.20]		
≥240	<.0001	1.26[1.25,1.28]	<.0001	1.20[1.17,1.23]	<.0001	1.11[1.06,1.16]	0.04	1.10[1.01,1.21]	0.22	1.08[0.95,1.23]		
				Prior CVD) (N =892,	607)						
Stage	1	Non-CKD	CK	XD Stage 3A	CK	D Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]		
<80	<.0001	0.88[0.87,0.89]	<.0001	0.94[0.92,0.95]	<.0001	0.94[0.91,0.96]	0.56	1.02[0.96,1.08]	0.37	0.96[0.89,1.04]		
80-<120	<.0001	0.95[0.94,0.96]	0.0002	0.97[0.95,0.99]	0.0003	0.96[0.93,0.98]	0.89	1.00[0.95,1.05]	0.70	0.99[0.92,1.06]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	<.0001	1.04[1.03,1.06]	0.05	1.02[1.00,1.04]	0.005	1.04[1.01,1.07]	0.35	1.03[0.97,1.09]	0.08	1.08[0.99,1.17]		
200-<240	<.0001	1.07[1.06,1.09]	<.0001	1.06[1.03,1.09]	0.03	1.04[1.00,1.07]	0.07	1.06[1.00,1.13]	0.11	1.08[0.98,1.19]		
≥240	<.0001	1.15[1.13,1.16]	<.0001	1.12[1.10,1.14]	<.0001	1.11[1.08,1.14]	0.001	1.10[1.04,1.16]	0.43	0.97[0.89,1.05]		

Model Adjustments: age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins, body mass index and albumin.

Witx + Edb duj				Age<65 year	s (N =1,59	4,293)				
Stage	I	Non-CKD	CK	XD Stage 3A	Ck	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.95[0.94,0.96]	0.44	1.02[0.97,1.07]	0.88	0.99[0.92,1.07]	0.002	1.19[1.07,1.33]	0.005	1.12[1.04,1.21]
80-<120	0.001	0.98[0.97,0.99]	0.21	1.02[0.99,1.06]	0.31	0.97[0.91,1.03]	0.18	1.07[0.97,1.18]	0.02	1.09[1.02,1.17]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.001	1.02[1.01,1.04]	0.20	1.03[0.99,1.07]	0.40	1.03[0.96,1.10]	0.49	1.04[0.94,1.15]	0.04	1.09[1.00,1.18]
200-<240	0.003	1.02[1.01,1.04]	0.51	1.02[0.97,1.06]	0.19	0.95[0.88,1.03]	0.36	1.05[0.94,1.18]	0.34	1.05[0.95,1.15]
≥240	<.0001	1.09[1.07,1.10]	<.0001	1.09[1.05,1.13]	0.77	0.99[0.94,1.05]	0.19	1.06[0.97,1.16]	0.93	1.00[0.93,1.08]
			_	Age ≥65 year					-	
Stage	1	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	1.04[1.03,1.05]	<.0001	1.05[1.04,1.07]	<.0001	1.06[1.04,1.08]	0.0002	1.08[1.04,1.13]	0.40	0.97[0.91,1.04]
80-<120	0.25	1.01[1.00,1.02]	0.10	1.01[1.00,1.03]	0.53	1.01[0.99,1.03]	0.60	1.01[0.97,1.05]	0.63	0.99[0.93,1.05]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.65	1.00[0.99,1.02]	0.35	1.01[0.99,1.03]	0.43	0.99[0.97,1.01]	0.91	1.00[0.96,1.04]	0.09	0.94[0.87,1.01]
200-<240	0.63	1.00[0.99,1.02]	0.42	1.01[0.99,1.03]	0.37	0.99[0.96,1.01]	0.003	0.93[0.88,0.98]	0.50	0.97[0.89,1.06]
≥240	<.0001	1.04[1.03,1.05]	<.0001	1.04[1.03,1.06]	0.17	1.02[0.99,1.04]	0.29	0.98[0.94,1.02]	0.01	0.90[0.83,0.97]
				Non-Diabetic		/ /				
Stage	ľ	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD Stage 5/ESR	
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.03	1.01[1.00,1.02]	<.0001	1.05[1.03,1.07]	<.0001	1.06[1.04,1.09]	0.004	1.08[1.03,1.14]	0.80	1.01[0.93,1.10]
80-<120	0.16	0.99[0.98,1.00]	0.07	1.02[1.00,1.03]	0.14	1.02[0.99,1.04]	0.28	1.03[0.98,1.08]	0.19	1.05[0.98,1.13]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.09	1.01[1.00,1.02]	0.32	1.01[0.99,1.03]	0.99	1.00[0.97,1.03]	0.56	0.98[0.93,1.04]	0.89	1.01[0.92,1.10]
200-<240	0.09	1.01[1.00,1.03]	0.95	1.00[0.98,1.03]	0.55	0.99[0.96,1.03]	0.47	0.98[0.91,1.05]	0.50	1.04[0.93,1.16]
≥240	<.0001	1.06[1.05,1.07]	0.0001	1.04[1.02,1.07]	0.26	1.02[0.99,1.05]	0.44	0.98[0.92,1.04]	0.57	0.97[0.89,1.07]
				Diabetics						
Stage	ľ	Non-CKD	CK	D Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.97[0.95,0.98]	0.01	1.04[1.01,1.06]	0.06	1.03[1.00,1.06]	0.0002	1.11[1.05,1.18]	0.11	1.06[0.99,1.13]
80-<120	0.17	0.99[0.98,1.00]	0.54	1.01[0.99,1.03]	0.16	0.98[0.95,1.01]	0.76	1.01[0.96,1.06]	0.52	1.02[0.96,1.08]

Table S6. Association of Baseline Serum Triglycerides with Time to Non-ASCVD Hospitalization across Strata under Case-Mix + Lab adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.002	1.03[1.01,1.04]	0.31	1.01[0.99,1.04]	0.52	0.99[0.96,1.02]	0.62	1.01[0.96,1.07]	0.77	1.01[0.94,1.08]
200-<240	0.004	1.03[1.01,1.05]	0.17	1.02[0.99,1.05]	0.35	0.98[0.95,1.02]	0.02	0.93[0.88,0.99]	0.66	0.98[0.91,1.07]
≥240	<.0001	1.09[1.08,1.11]	<.0001	1.07[1.04,1.09]	0.59	1.01[0.98,1.04]	0.89	1.00[0.96,1.05]	0.02	0.93[0.87,0.99]
				LDL <100 mg/	dL (N =1,	300,948)				
Stage	1	Non-CKD	CK	XD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.001	1.02[1.01,1.03]	<.0001	1.06[1.04,1.08]	<.0001	1.08[1.05,1.11]	<.0001	1.13[1.08,1.18]	0.21	1.04[0.98,1.11]
80-<120	0.53	1.00[0.99,1.02]	0.21	1.01[0.99,1.03]	0.95	1.00[0.98,1.02]	0.005	1.06[1.02,1.11]	0.36	1.03[0.97,1.09]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.42	1.01[0.99,1.02]	0.84	1.00[0.98,1.02]	0.10	0.98[0.95,1.01]	0.50	1.02[0.97,1.07]	0.97	1.00[0.93,1.08]
200-<240	0.998	1.00[0.98,1.02]	0.12	0.98[0.96,1.01]	0.63	0.99[0.96,1.03]	0.03	0.94[0.88,0.99]	0.34	0.96[0.88,1.04]
≥240	<.0001	1.05[1.04,1.07]	0.0003	1.04[1.02,1.06]	0.84	1.00[0.98,1.03]	0.88	1.00[0.95,1.05]	0.002	0.90[0.84,0.96]
				LDL ≥100 mg/	dL (N = 1,	608,920)	•		•	
Stage	I	Non-CKD	CK	KD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	<.0001	0.97[0.96,0.98]	0.34	1.01[0.99,1.04]	0.23	0.98[0.94,1.01]	0.13	1.06[0.98,1.14]	0.15	0.92[0.83,1.03]
80-<120	0.003	0.98[0.97,1.00]	0.18	1.01[0.99,1.03]	0.65	1.01[0.98,1.04]	0.03	0.94[0.89,1.00]	0.92	1.00[0.92,1.08]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.001	1.02[1.01,1.04]	0.03	1.03[1.00,1.05]	0.29	1.02[0.99,1.05]	0.60	0.98[0.93,1.05]	0.77	1.01[0.92,1.12]
200-<240	<.0001	1.03[1.02,1.05]	0.002	1.05[1.02,1.08]	0.25	0.98[0.94,1.02]	0.42	0.97[0.91,1.04]	0.14	1.08[0.98,1.20]
≥240	<.0001	1.09[1.08,1.11]	<.0001	1.08[1.05,1.11]	0.02	1.04[1.01,1.07]	0.79	0.99[0.93,1.05]	0.38	1.04[0.95,1.14]
				No Statin Prescri	ption (N =	1,466,566)				
Stage	1	Non-CKD	CK	KD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.14	1.01[1.00,1.02]	0.0001	1.05[1.02,1.07]	0.001	1.06[1.02,1.09]	<.0001	1.17[1.10,1.25]	0.54	0.98[0.91,1.05]
80-<120	0.59	1.00[0.99,1.01]	0.22	1.01[0.99,1.04]	0.30	1.02[0.99,1.05]	0.09	1.05[0.99,1.11]	0.67	1.02[0.95,1.09]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.88	1.00[0.99,1.02]	0.66	0.99[0.97,1.02]	0.54	0.99[0.95,1.03]	0.11	1.06[0.99,1.13]	0.01	0.89[0.82,0.98]
200-<240	0.29	1.01[0.99,1.03]	0.92	1.00[0.97,1.03]	0.78	0.99[0.95,1.04]	0.42	0.97[0.89,1.05]	0.57	1.03[0.93,1.14]
≥240	<.0001	1.05[1.03,1.06]	0.06	1.03[1.00,1.05]	0.63	1.01[0.97,1.05]	0.09	1.06[0.99,1.13]	0.02	0.91[0.83,0.99]
				Statin Prescript		, , ,				
Stage	1	Non-CKD	CK	KD Stage 3A	CK	KD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.77	1.00[0.99,1.01]	<.0001	1.05[1.03,1.07]	0.0004	1.05[1.02,1.08]	0.04	1.05[1.00,1.11]	0.02	1.09[1.02,1.17]

80-<120	0.14	0.99[0.98,1.00]	0.08	1.01[1.00,1.03]	0.52	0.99[0.97,1.02]	0.95	1.00[0.96,1.04]	0.14	1.05[0.98,1.11]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	0.0004	1.02[1.01,1.04]	0.04	1.02[1.00,1.04]	0.82	1.00[0.97,1.02]	0.24	0.97[0.93,1.02]	0.01	1.10[1.02,1.18]		
200-<240	0.01	1.02[1.01,1.03]	0.34	1.01[0.99,1.04]	0.19	0.98[0.95,1.01]	0.03	0.94[0.89,0.99]	0.84	0.99[0.91,1.08]		
≥240	<.0001	1.09[1.08,1.10]	<.0001	1.08[1.06,1.10]	0.19	1.02[0.99,1.04]	0.10	0.96[0.92,1.01]	0.42	0.97[0.91,1.04]		
No Prior CVD (N = 2,070,569)												
Stage	Stage Non-CKD			XD Stage 3A	CK	XD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]		
<80	0.03	0.99[0.98,1.00]	0.04	1.02[1.00,1.05]	0.10	1.03[0.99,1.07]	0.09	1.06[0.99,1.14]	0.55	0.97[0.89,1.06]		
80-<120	0.02	0.99[0.98,1.00]	0.48	1.01[0.99,1.03]	0.69	0.99[0.96,1.03]	0.40	0.97[0.92,1.04]	0.82	1.01[0.93,1.09]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	0.02	1.01[1.00,1.03]	0.74	1.00[0.98,1.03]	0.69	1.01[0.97,1.05]	0.93	1.00[0.93,1.08]	0.57	0.97[0.89,1.07]		
200-<240	0.0002	1.03[1.01,1.04]	0.36	1.01[0.99,1.04]	0.68	0.99[0.95,1.04]	0.90	1.01[0.93,1.09]	0.42	0.96[0.86,1.07]		
≥240	<.0001	1.08[1.07,1.09]	<.0001	1.05[1.03,1.08]	0.03	1.04[1.00,1.08]	0.38	1.03[0.96,1.10]	0.92	1.01[0.92,1.10]		
				Prior CVD) (N =892,	607)						
Stage	1	Non-CKD	CK	XD Stage 3A	CK	XD Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD		
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]		
<80	<.0001	1.03[1.02,1.04]	<.0001	1.07[1.05,1.09]	<.0001	1.06[1.04,1.09]	<.0001	1.11[1.06,1.16]	0.02	1.08[1.01,1.15]		
80-<120	0.57	1.00[0.99,1.02]	0.03	1.02[1.00,1.04]	0.56	1.01[0.99,1.03]	0.10	1.03[0.99,1.08]	0.08	1.05[0.99,1.11]		
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		
160-<200	0.12	1.01[1.00,1.03]	0.17	1.01[0.99,1.04]	0.39	0.99[0.96,1.02]	0.97	1.00[0.95,1.05]	0.41	1.03[0.96,1.10]		
200-<240	1.00	1.00[0.98,1.02]	0.66	1.01[0.98,1.03]	0.30	0.98[0.96,1.01]	0.01	0.93[0.88,0.98]	0.53	1.03[0.95,1.11]		
≥240	<.0001	1.06[1.05,1.08]	<.0001	1.06[1.04,1.08]	0.71	1.01[0.98,1.03]	0.35	0.98[0.94,1.02]	0.01	0.91[0.85,0.98]		

Model Adjustments: age, sex, race, ethnicity, ever smoker, ever alcoholism, Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins, body mass index and albumin.

Struttied Sy	Dustinit	CKD Stage act			djusted					
Baseline Stage	N	lon-CKD	СК	D Stage 3A	CK	D Stage 3B	С	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	0.87[0.86,0.88]	0.573	1.00[0.99,1.02]	0.01	1.03[1.01,1.05]	0.18	1.03[0.99,1.08]	0.02	1.08[1.01,1.15]
80-<120	0.001	0.99[0.98,0.99]	0.01	1.02[1.01,1.03]	0.96	1.00[0.98,1.02]	0.43	1.02[0.98,1.06]	0.18	1.04[0.98,1.10]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.90	1.00[0.99,1.01]	0.59	1.00[0.98,1.01]	0.373	0.99[0.96,1.01]	0.16	0.96[0.92,1.01]	0.01	0.90[0.84,0.97]
200-<240	0.06	0.99[0.98,1.00]	0.10	0.98[0.96,1.00]	0.76	1.00[0.97,1.03]	0.48	0.98[0.92,1.04]	0.21	0.95[0.87,1.03]
≥240	0.03	0.99[0.98,1.00]	0.841	1.00[0.98,1.02]	0.104	0.98[0.95,1.00]	0.01	0.93[0.89,0.98]	< 0.0001	0.87[0.81,0.93]
Age Adjusted										
Baseline Stage	Ň	on-CKD	СК	D Stage 3A	СК	D Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	0.82[0.81,0.83]	< 0.0001	0.95[0.93,0.96]	0.99	1.00[0.98,1.02]	0.91	1.00[0.95,1.04]	0.14	1.05[0.98,1.12]
80-<120	< 0.0001	0.94[0.93,0.94]	0.08	0.99[0.97,1.00]	0.11	0.98[0.96,1.00]	0.99	1.00[0.96,1.04]	0.53	1.02[0.96,1.08]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	< 0.0001	1.06[1.04,1.07]	0.01	1.03[1.01,1.04]	0.79	1.00[0.98,1.03]	0.45	0.98[0.93,1.03]	0.04	0.92[0.86,1.00]
200-<240	< 0.0001	1.10[1.08,1.11]	0.001	1.04[1.01,1.06]	0.16	1.02[0.99,1.05]	0.69	1.01[0.95,1.07]	0.78	0.99[0.91,1.08]
≥240	< 0.0001	1.22[1.21,1.23]	0	1.11[1.09,1.13]	0.02	1.03[1.00,1.06]	0.82	0.99[0.95,1.04]	0.23	0.96[0.89,1.03]
				Case-M	ix Adjusted			·		
Baseline Stage	N	lon-CKD	CK	D Stage 3A	СК	D Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	0.96[0.95,0.97]	0.89	1.00[0.99,1.02]	0.03	1.03[1.00,1.05]	0.16	1.03[0.99,1.08]	0.04	1.07[1.00,1.14]
80-<120	0.08	0.99[0.98,1.00]	0.13	1.01[1.00,1.03]	0.69	1.00[0.98,1.02]	0.18	1.03[0.99,1.07]	0.94	1.00[0.94,1.06]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.09	1.01[1.00,1.02]	0.84	1.00[0.98,1.02]	0.82	1.00[0.97,1.02]	0.15	0.96[0.92,1.01]	0.11	0.94[0.87,1.01]
200-<240	0.08	1.01[1.00,1.02]	0.92	1.00[0.98,1.02]	0.73	0.99[0.97,1.02]	0.93	1.00[0.94,1.06]	0.18	0.94[0.86,1.03]
≥240	< 0.0001	1.04[1.03,1.05]	0.19	1.01[0.99,1.03]	0.04	0.97[0.95,1.00]	0.01	0.93[0.89,0.98]	< 0.0001	0.88[0.81,0.94]
				Case-Mix+	Lab Adjus					
Baseline Stage	Ň	on-CKD	CK	D Stage 3A	СК	D Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	0.86[0.85,0.86]	< 0.0001	0.91[0.90,0.93]	< 0.0001	0.94[0.92,0.96]	0.02	0.95[0.90,0.99]	0.38	0.97[0.91,1.04]
80-<120	< 0.0001	0.95[0.94,0.96]	< 0.0001	0.97[0.96,0.99]	< 0.0001	0.96[0.94,0.98]	0.60	0.99[0.95,1.03]	0.36	0.97[0.92,1.03]

Table S7. Hazard Ratios for the Association of Time-Varying Serum Triglycerides with Time to ASCVD HospitalizationStratified by Baseline CKD Stage across levels of adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	< 0.0001	1.04[1.03,1.05]	0.003	1.03[1.01,1.04]	0.14	1.02[0.99,1.04]	0.64	0.99[0.94,1.04]	0.51	0.98[0.91,1.05]
200-<240	< 0.0001	1.06[1.04,1.07]	< 0.0001	1.04[1.02,1.06]	0.03	1.03[1.00,1.07]	0.21	1.04[0.98,1.10]	0.97	1.00[0.92,1.09]
≥240	< 0.0001	1.10[1.09,1.11]	< 0.0001	1.07[1.05,1.09]	0.03	1.03[1.00,1.06]	0.96	1.00[0.95,1.05]	0.39	0.97[0.90,1.04]
	Case-Mix+Lab+Lipid Adjusted									
Baseline Stage	N	on-CKD	CK	D Stage 3A	CK	D Stage 3B	C	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	0.94[0.93,0.95]	0.019	0.98[0.96,1.00]	0.75	1.00[0.98,1.03]	0.81	0.99[0.95,1.04]	0.95	1.00[0.94,1.07]
80-<120	< 0.0001	0.98[0.97,0.99]	0.79	1.00[0.98,1.01]	0.09	0.98[0.96,1.00]	0.70	1.01[0.97,1.05]	0.66	0.99[0.93,1.05]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	< 0.0001	1.02[1.01,1.03]	0.16	1.01[1.00,1.03]	0.672	1.01[0.98,1.03]	0.35	0.98[0.93,1.03]	0.39	0.97[0.90,1.04]
200-<240	< 0.0001	1.03[1.02,1.05]	0.04	1.02[1.00,1.05]	0.34	1.01[0.98,1.05]	0.51	1.02[0.96,1.08]	0.77	0.99[0.91,1.08]
≥240	< 0.0001	1.07[1.06,1.08]	< 0.0001	1.04[1.03,1.06]	0.653	1.01[0.98,1.03]	0.37	0.98[0.93,1.03]	0.17	0.95[0.88,1.02]

Model Adjustments:

Unadjusted

Age Adjusted: age

Case-Mix Adjusted: age, sex, race, ethnicity, ever smoker and ever alcoholism as well as time-updated Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins, and time-updated CKD stage

Case-Mix+Lab Adjusted: Case-Mix covariates and time-updated body mass index and albumin

Case-Mix+Lab+Lipid Adjusted: Case-Mix+Lab covariates and time-updated HDL and LDL cholesterols

		CKD Stage act		U U	adjusted					
Baseline Stage	N	on-CKD	СК	D Stage 3A	CK	D Stage 3B	CF	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	1.08[1.07,1.09]	< 0.0001	1.23[1.22,1.25]	< 0.0001	1.27[1.25,1.30]	< 0.0001	1.34[1.30,1.39]	< 0.0001	1.20[1.14,1.26]
80-<120	< 0.0001	1.06[1.05,1.07]	< 0.0001	1.10[1.08,1.11]	< 0.0001	1.10[1.08,1.12]	< 0.0001	1.14[1.10,1.18]	0.004	1.07[1.02,1.12]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	< 0.0001	0.95[0.94,0.96]	< 0.0001	0.93[0.92,0.95]	< 0.0001	0.93[0.91,0.95]	0.01	0.94[0.91,0.98]	< 0.0001	0.88[0.83,0.93]
200-<240	< 0.0001	0.91[0.90,0.92]	< 0.0001	0.89[0.88,0.91]	< 0.0001	0.92[0.90,0.95]	< 0.0001	0.90[0.86,0.94]	< 0.0001	0.87[0.81,0.92]
≥240	< 0.0001	0.86[0.85,0.87]	< 0.0001	0.88[0.86,0.89]	< 0.0001	0.86[0.84,0.88]	< 0.0001	0.87[0.84,0.91]	< 0.0001	0.74[0.70,0.79]
Age Adjusted										
Baseline Stage	N	on-CKD	СК	D Stage 3A	CK	D Stage 3B	Cŀ	XD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	1.03[1.03,1.04]	< 0.0001	1.16[1.14,1.17]	< 0.0001	1.23[1.21,1.26]	< 0.0001	1.32[1.27,1.36]	< 0.0001	1.18[1.13,1.24]
80-<120	< 0.0001	1.01[1.01,1.02]	< 0.0001	1.06[1.04,1.07]	< 0.0001	1.08[1.06,1.10]	< 0.0001	1.13[1.10,1.17]	0.01	1.06[1.01,1.11]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.86	1.00[0.99,1.01]	< 0.0001	0.97[0.95,0.98]	< 0.0001	0.95[0.92,0.97]	0.04	0.96[0.92,1.00]	< 0.0001	0.89[0.84,0.94]
200-<240	0.96	1.00[0.99,1.01]	< 0.0001	0.95[0.93,0.97]	< 0.0001	0.95[0.93,0.98]	0.001	0.92[0.88,0.97]	< 0.0001	0.88[0.83,0.94]
≥240	< 0.0001	1.06[1.05,1.07]	0.30	0.99[0.97,1.01]	< 0.0001	0.91[0.89,0.93]	< 0.0001	0.92[0.88,0.95]	< 0.0001	0.78[0.74,0.83]
				Case-M	lix Adjusted	1				
Baseline Stage	N	on-CKD	CK	D Stage 3A	CKD Stage 3B		CKD Stage 4		CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	1.10[1.09,1.11]	< 0.0001	1.15[1.14,1.17]	< 0.0001	1.19[1.17,1.22]	< 0.0001	1.26[1.22,1.31]	< 0.0001	1.13[1.08,1.19]
80-<120	< 0.0001	1.05[1.04,1.06]	< 0.0001	1.06[1.05,1.07]	< 0.0001	1.08[1.06,1.09]	< 0.0001	1.12[1.09,1.16]	0.13	1.04[0.99,1.08]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	< 0.0001	0.97[0.96,0.98]	< 0.0001	0.95[0.93,0.96]	< 0.0001	0.94[0.92,0.96]	0.03	0.96[0.92,1.00]	0.002	0.91[0.86,0.97]
200-<240	< 0.0001	0.95[0.94,0.96]	< 0.0001	0.92[0.90,0.93]	< 0.0001	0.93[0.91,0.96]	< 0.0001	0.89[0.85,0.93]	0.001	0.89[0.83,0.95]
≥240	< 0.0001	0.93[0.92,0.94]	< 0.0001	0.90[0.89,0.92]	< 0.0001	0.87[0.85,0.89]	< 0.0001	0.88[0.84,0.91]	< 0.0001	0.78[0.74,0.82]
	1		1		+Lab Adjus		1		1	
Baseline Stage	N	on-CKD	СК	D Stage 3A	CK	D Stage 3B	Cŀ	XD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	0.002	1.01[1.00,1.02]	< 0.0001	1.06[1.05,1.08]	< 0.0001	1.10[1.08,1.12]	< 0.0001	1.15[1.11,1.19]	0.20	1.03[0.98,1.08]
80-<120	0.001	1.01[1.01,1.02]	< 0.0001	1.03[1.01,1.04]	< 0.0001	1.04[1.02,1.06]	< 0.0001	1.08[1.05,1.12]	0.81	1.01[0.96,1.05]

Table S8. Hazard Ratios for the Association of Time-Varying Serum Triglycerides with Time to Non-ASCVD HospitalizationStratified by Baseline CKD Stage across levels of adjustment.

120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.09	0.99[0.98,1.00]	< 0.0001	0.97[0.95,0.99]	< 0.0001	0.96[0.94,0.98]	0.28	0.98[0.94,1.02]	0.15	0.96[0.91,1.02]
200-<240	0.002	0.98[0.97,0.99]	< 0.0001	0.95[0.93,0.97]	0.02	0.97[0.94,0.99]	0.004	0.93[0.89,0.98]	0.17	0.95[0.89,1.02]
≥240	< 0.0001	0.98[0.97,0.99]	< 0.0001	0.95[0.93,0.96]	< 0.0001	0.92[0.90,0.94]	0.01	0.94[0.91,0.98]	< 0.0001	0.86[0.81,0.91]
	Case-Mix+Lab+Lipid Adjusted									
Baseline Stage	Ň	lon-CKD	CK	D Stage 3A	CK	D Stage 3B	CH	KD Stage 4	CKD	Stage 5/ESRD
Serum Triglycerides Group (mg/dL)	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]	Р	HR[95%CI]
<80	< 0.0001	1.02[1.01,1.03]	< 0.0001	1.08[1.06,1.09]	< 0.0001	1.11[1.09,1.13]	< 0.0001	1.16[1.11,1.20]	0.38	1.02[0.97,1.08]
80-<120	< 0.0001	1.02[1.01,1.02]	< 0.0001	1.03[1.02,1.05]	< 0.0001	1.04[1.02,1.06]	< 0.0001	1.08[1.05,1.12]	0.96	1.00[0.96,1.05]
120-<160	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
160-<200	0.05	0.99[0.98,1.00]	< 0.0001	0.97[0.95,0.98]	< 0.0001	0.96[0.94,0.98]	0.22	0.98[0.94,1.02]	0.16	0.96[0.91,1.02]
200-<240	0.001	0.98[0.97,0.99]	< 0.0001	0.95[0.93,0.97]	0.01	0.96[0.94,0.99]	0.003	0.93[0.88,0.97]	0.20	0.96[0.90,1.02]
≥240	< 0.0001	0.98[0.97,0.99]	< 0.0001	0.94[0.92,0.96]	< 0.0001	0.91[0.89,0.94]	0.001	0.94[0.90,0.97]	< 0.0001	0.85[0.80,0.90]

Model Adjustments:

Unadjusted

Age Adjusted: age

Case-Mix Adjusted: age, sex, race, ethnicity, ever smoker and ever alcoholism as well as time-updated Charlson comorbidity index, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disorder, dementia, liver disease, cancer, diabetes, atrial fibrillation, hypertension, depression, ischemic heart disease, prescription of statins and prescription of non-statins, and time-updated CKD stage

Case-Mix+Lab Adjusted: Case-Mix covariates and time-updated body mass index and albumin

Case-Mix+Lab+Lipid Adjusted: Case-Mix+Lab covariates and time-updated HDL and LDL cholesterols

Figure S1. Cohort Construction.




Figure S2. Association of Baseline Triglycerides with Time to A) ASCVD and B) Non-ASCVD Hospitalization Across CKD Stages after adjustment for Case-Mix + Lab + Log Transformed UACR among N=194,801 patients with UACR data.

